



April 27, 2001 / Vol. 50 / No. RR-5

**MMWR**<sup>TM</sup>  
MORBIDITY AND MORTALITY  
WEEKLY REPORT

***Recommendations  
and  
Reports***

***Inside: Continuing Education Examination***

**Recommendations for Preventing  
Transmission of Infections Among  
Chronic Hemodialysis Patients**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Centers for Disease Control and Prevention (CDC)  
Atlanta, GA 30333



The *MMWR* series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

**SUGGESTED CITATION**

Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. *MMWR* 2001;50(No. RR-5):[inclusive page numbers].

Centers for Disease Control and Prevention ..... Jeffrey P. Koplan, M.D., M.P.H.  
*Director*

The material in this report was prepared for publication by  
National Center for Infectious Diseases ..... James M. Hughes, M.D.  
*Director*

Division of Viral and Rickettsial Diseases ..... James W. LeDuc, Ph.D.  
*Acting Director*

The production of this report as an *MMWR* serial publication was coordinated in  
Epidemiology Program Office ..... Stephen B. Thacker, M.D., M.Sc.  
*Director*

Office of Scientific and Health Communications ..... John W. Ward, M.D.  
*Director*  
*Editor, MMWR Series*

*Recommendations and Reports* ..... Suzanne M. Hewitt, M.P.A.  
*Managing Editor*

Amanda Crowell  
*Project Editor*

Beverly J. Holland  
*Visual Information Specialist*

Michele D. Renshaw  
Erica R. Shaver  
*Information Technology Specialists*

## Contents

Introduction .....	1
Background .....	2
Hepatitis B Virus Infection .....	2
Epidemiology .....	2
Clinical Features and Natural History .....	4
Screening and Diagnostic Tests .....	5
Hepatitis B Vaccine .....	6
Hepatitis C Virus Infection .....	9
Epidemiology .....	9
Clinical Features and Natural History .....	10
Screening and Diagnostic Tests .....	11
Other Bloodborne Viruses .....	12
Hepatitis Delta Virus Infection .....	12
Human Immunodeficiency Virus Infection .....	12
Bacterial Infections .....	13
Epidemiology .....	13
Antimicrobial Resistance .....	14
Vancomycin Use .....	15
Equipment, Supplies, and Environmental Surfaces .....	15
Sterilization, Disinfection, and Cleaning .....	15
Infection Control Precautions for Outpatient Hemodialysis Settings Compared with Inpatient Hospital Settings .....	17
Recommendations .....	18
Rationale .....	18
Infection Control Practices for Hemodialysis Units .....	19
Infection Control Precautions for All Patients .....	19
Routine Serologic Testing .....	24
Hepatitis B Vaccination .....	25
Prevention and Management of HBV Infection .....	26
Prevention and Management of HCV Infection .....	28
Prevention and Management of HDV Infection .....	29
Prevention and Management of HIV Infection .....	29
Prevention and Management of Bacterial Infections .....	30
Surveillance for Infections and Other Adverse Events .....	30
Infection Control Training and Education .....	30
Future Directions .....	31
References .....	32
Suggested Readings .....	42
Continuing Education Examination .....	CE-1

## Terms and Abbreviations Used in This Publication

Acute hepatitis B	Newly acquired symptomatic hepatitis B virus (HBV) infection.
Acute hepatitis C	Newly acquired symptomatic hepatitis C virus (HCV) infection.
ALT	Alanine aminotransferase, previously called SGPT.
Anti-HBc	Antibody to hepatitis B core antigen.
Anti-HBe	Antibody to hepatitis B e antigen.
Anti-HBs	Antibody to hepatitis B surface antigen.
Anti-HCV	Antibody to hepatitis C virus.
Anti-HDV	Antibody to hepatitis D virus.
AST	Aspartate aminotransferase, previously called SGOT.
AV	Arteriovenous.
Chronic (persistent) HBV infection	Persistent infection with HBV; characterized by detection of HBsAg >6 months after newly acquired infection.
Chronic (persistent) HCV infection	Persistent infection with HCV; characterized by detection of HCV RNA >6 months after newly acquired infection.
Chronic hepatitis B	Liver inflammation in patients with chronic HBV infection; characterized by abnormal levels of liver enzymes.
Chronic hepatitis C	Liver inflammation in patients with chronic HCV infection; characterized by abnormal levels of liver enzymes.
CNS	Coagulase negative staphylococci.
EIA	Enzyme immunoassay.
EPA	U.S. Environmental Protection Agency.
ESRD	End-stage renal disease.
FDA	U.S. Food and Drug Administration.
GISA	Glycopeptide-resistant <i>Staphylococcus aureus</i> .
HBcAg	Hepatitis B core antigen
HBeAg	Hepatitis B e antigen.
HBsAg	Hepatitis B surface antigen.
HBV	Hepatitis B virus.
HBV DNA	Hepatitis B virus deoxyribonucleic acid.
HCV	Hepatitis C virus.
HCV RNA	Hepatitis C virus ribonucleic acid.
HDV	Hepatitis D virus.
HIV	Human immunodeficiency virus.
Isolated anti-HBc	Anti-HBc positive, HBsAg negative, and anti-HBs negative.
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i> .
NNIS	National Nosocomial Infections Surveillance system.
RIBA™	Recombinant immunoblot assay.
RT-PCR	Reverse transcriptase polymerase chain reaction.
SGOT	Serum glutamic-oxaloacetic transaminase, now called AST.
SGPT	Serum glutamic-pyruvic transaminase, now called ALT.
VISA	Vancomycin-intermediate <i>Staphylococcus aureus</i> .
VRE	Vancomycin-resistant enterococci.

**Consultant Meeting to Update Recommendations for the  
Prevention and Control of Bloodborne and Other Infections  
Among Chronic Hemodialysis Patients**

**October 5–6, 1999  
Atlanta, Georgia**

**EXPERT CONSULTANTS**

James L. Bailey, M.D.  
Emory University School of Medicine  
Atlanta, Georgia

Paul Balter, M.D.  
Everest Health Care  
Oakville, Illinois

Jeffrey Berns, M.D.  
American Society of Nephrology  
Washington, D.C.

Evelyn Butera, M.S.  
Satellite Dialysis Center  
Redwood City, California

Thomas Depner, M.D.  
American Society for Artificial Internal  
Organs  
Boca Raton, Florida

Claudia Douglas  
Hackensack University Medical Center  
Hackensack, New Jersey

Evelyn Duncan  
Everest Health Care  
Oakville, Illinois

B.F. Edwards, M.D.  
Emory University School of Medicine  
Atlanta, Georgia

Martin S. Favero, Ph.D.  
Advanced Sterilization Products  
Irvine, California

John Foreman, M.D.  
American Society of Pediatric Nephrology  
Cleveland, Ohio

Michael W. Fried, M.D.  
University of North Carolina  
Chapel Hill, North Carolina

Vasant Gandhi, M.D.  
Vines Veteran's Administration Hospital  
Vines, Illinois

Clifford Glynn  
National Association of Nephrology  
Technicians  
Dayton, Ohio

Ray Hakim, M.D., Ph.D.  
Renal Care Group, Inc.  
Nashville Tennessee

Norma Heard  
Grady Dialysis Unit  
Atlanta, Georgia

J. Michael Lazarus, M.D.  
Fresenius Medical Care, NA  
Lexington, Massachusetts

Nathan Levin, M.D.  
Association for the Advancement of Medical  
Instrumentation  
New York, New York

Paul Light, M.D.  
Forum of ESRD Networks  
Baltimore, Maryland

Stan Lindenfield, M.D.  
Total Renal Care  
Torrance, California

Cynthia Marshall  
Renal Treatment Center  
Atlanta, Georgia

Bela T. Matyas, M.D., M.P.H.  
Council of State and Territorial  
Epidemiologists  
Atlanta, Georgia

Joseph Mazilli  
Hackensack University Medical Center  
Hackensack, New Jersey

Barbara McCool, M.S.  
U.S. Food and Drug Administration  
Rockville, Maryland

**EXPERT CONSULTANTS—CONTINUED**

Ira Meisels, M.D.  
Renal Physicians Association  
Rockville, Maryland

Catherine M. Meyers, M.D.  
U.S. Food and Drug Administration  
Rockville, Maryland

Svetlozar Natov, M.D.  
Tufts University School of Medicine  
Newton, Massachusetts

Cathy D. Nutter  
U.S. Food and Drug Administration  
Rockville, Maryland

Stephen Pastan, M.D.  
Emory University School of Medicine  
Atlanta, Georgia

Eileen Peacock, M.S.N.  
Total Renal Care  
Maple Glen, Pennsylvania

Jacquelyn Polder, M.P.H.  
Health Care Financing Administration  
Seattle, Washington

Robert Sharbaugh, Ph.D.  
Association for Professionals in Infection  
Control, Inc.  
Charleston, South Carolina

Gayle Shimokura  
University of North Carolina  
Chapel Hill, North Carolina

James Steinberg, M.D.  
Emory University School of Medicine  
Atlanta, Georgia

Charlotte Thomas-Hawkins, Ph.D.  
American Nephrology Nurses Association  
Pitman, New Jersey

Stephen Vas, M.D.  
Toronto Western Hospital  
Toronto, Ontario, Canada

Brian A.J. Walters, Ph.D.  
Gambro Healthcare  
Ft Lauderdale, Florida

David J. Weber, M.D.  
University of North Carolina-Chapel Hill  
Medical School  
Chapel Hill, North Carolina

Rebecca Wingard, M.S.N.  
Renal Care Group, Inc.  
Nashville, Tennessee

Jay Wish, M.D.  
Forum of ESRD Networks  
Cleveland, Ohio

**AGENCY LIAISON CONSULTANT**

Paul W. Eggers, Ph.D.  
Health Care Financing Administration  
Baltimore, Maryland

**The following CDC staff members prepared this report:**

Miriam J. Alter, Ph.D.  
Rob L. Lyerla, Ph.D.  
*Division of Viral and Rickettsial Diseases  
National Center for Infectious Diseases*

Jerome I. Tokars, M.D., M.P.H.  
Elaine R. Miller, M.P.H.  
Matthew J. Arduino, M.S., Dr.P.H.  
*Hospital Infections Program  
National Center for Infectious Diseases*

**in consultation with**  
Lawrence Y.C. Agodoa, M.D.  
*National Institute of Diabetes and Digestive and Kidney Diseases  
National Institutes of Health*

Carolyn Y. Neuland, Ph.D.  
*Center for Devices and Radiologic Health  
U.S. Food and Drug Administration*





# Recommendations for Preventing Transmission of Infections Among Chronic Hemodialysis Patients

## Summary

*These recommendations replace previous recommendations for the prevention of bloodborne virus infections in hemodialysis centers and provide additional recommendations for the prevention of bacterial infections in this setting. The recommendations in this report provide guidelines for a comprehensive infection control program that includes a) infection control practices specifically designed for the hemodialysis setting, including routine serologic testing and immunization; b) surveillance; and c) training and education. Implementation of this program in hemodialysis centers will reduce opportunities for patient-to-patient transmission of infectious agents, directly or indirectly via contaminated devices, equipment and supplies, environmental surfaces, or hands of personnel. Based on available knowledge, these recommendations were developed by CDC after consultation with staff members from other federal agencies and specialists in the field who met in Atlanta on October 5–6, 1999. They are summarized in the Recommendations section. This report is intended to serve as a resource for health-care professionals, public health officials, and organizations involved in the care of patients receiving hemodialysis.*

## INTRODUCTION

The number of patients with end-stage renal disease treated by maintenance hemodialysis in the United States has increased sharply during the past 30 years. In 1999, more than 3,000 hemodialysis centers had >190,000 chronic hemodialysis patients and >60,000 staff members (1). Chronic hemodialysis patients are at high risk for infection because the process of hemodialysis requires vascular access for prolonged periods. In an environment where multiple patients receive dialysis concurrently, repeated opportunities exist for person-to-person transmission of infectious agents, directly or indirectly via contaminated devices, equipment and supplies, environmental surfaces, or hands of personnel. Furthermore, hemodialysis patients are immunosuppressed (2), which increases their susceptibility to infection, and they require frequent hospitalizations and surgery, which increases their opportunities for exposure to nosocomial infections.

Historically, surveillance for infections associated with chronic hemodialysis focused on viral hepatitis, particularly hepatitis B virus (HBV) infection. CDC began conducting national surveillance for hemodialysis-associated hepatitis in 1972 (3,4). Since 1976, this surveillance has been performed in collaboration with the Health Care Financing Administration (HCFA) during its annual facility survey. Other hemodialysis-associated diseases and practices not related to hepatitis have been included over the years (e.g., pyrogenic reactions, dialysis dementia, vascular access infections, reuse practices, vancomycin use), and the system is continually updated to collect data regarding hemodialysis-associated practices and diseases of current interest and importance (5–18).

Recommendations for the control of hepatitis B in hemodialysis centers were first published in 1977 (19), and by 1980, their widespread implementation was associated with a sharp reduction in incidence of HBV infection among both patients and staff members (5). In 1982, hepatitis B vaccination was recommended for all susceptible patients and staff members (20). However, outbreaks of both HBV and hepatitis C virus (HCV) infections continue to occur among chronic hemodialysis patients. Epidemiologic investigations have indicated substantial deficiencies in recommended infection control practices, as well as a failure to vaccinate hemodialysis patients against hepatitis B (21,22). These practices apparently are not being fully implemented because staff members a) are not aware of the practices and their importance, b) are confused regarding the differences between standard (i.e., universal) precautions recommended for all health-care settings and the additional precautions necessary in the hemodialysis setting, and c) believe that hepatitis B vaccine is ineffective for preventing HBV infection in chronic hemodialysis patients (22).

Bacterial infections, especially those involving vascular access, are the most frequent infectious complication of hemodialysis and a major cause of morbidity and mortality among hemodialysis patients (1). During the 1990s, the prevalence of antimicrobial-resistant bacteria (e.g., methicillin-resistant *Staphylococcus aureus* [MRSA] and vancomycin-resistant enterococci [VRE]) increased rapidly in health-care settings, including hemodialysis units (18,23). Although numerous outbreaks of bacterial infections in the hemodialysis setting have been reported (24), few studies exist regarding the epidemiology and prevention of endemically occurring bacterial infections in hemodialysis patients, and formal recommendations to prevent such infections have not been published previously. In 1999, CDC initiated a surveillance system for bloodstream and vascular access infections in outpatient hemodialysis centers to determine the frequency of and risk factors for these complications in order to formulate and evaluate strategies for control (25).

The recommendations contained in this report were developed by reviewing available data and are based on consultations with specialists in the field. These recommendations provide guidelines for infection control strategies, unique to the hemodialysis setting, that should be used to prevent patient-to-patient transmission of bloodborne viruses and pathogenic bacteria. They are summarized on pages 20–21.

These recommendations do not address sources of bacterial and chemical contaminants in dialysis systems, water treatment or distribution, specific procedures for reprocessing dialyzers, clinical practice methods to prevent bacterial infections (e.g., techniques for skin preparation and access), or comprehensive strategies for preventing infections among health-care workers (see Suggested Readings for information on these topics).

## BACKGROUND

### Hepatitis B Virus Infection

#### *Epidemiology*

**Incidence and Prevalence.** In 1974, the incidence of newly acquired (i.e., acute) HBV infection among chronic hemodialysis patients in the United States was 6.2%, and se-

lected hemodialysis centers reported rates as high as 30% (4). By 1980, nationwide incidence among patients had decreased to 1% (5), and by 1999, to 0.06% (18) (CDC, unpublished data, 2001), with only 3.5% of all centers reporting newly acquired infections. Prevalence of chronic HBV infection (i.e., hepatitis B surface antigen [HBsAg] positivity) among hemodialysis patients declined from 7.8% in 1976 to 3.8% in 1980 and to 0.9% by 1999 (5,18) (CDC, unpublished data, 2001). In 1999, a total of 27.7% of 3,483 centers provided dialysis to  $\geq 1$  patient with either acute or chronic HBV infection (CDC, unpublished data, 2001).

**Transmission.** HBV is transmitted by percutaneous (i.e., puncture through the skin) or permucosal (i.e., direct contact with mucous membranes) exposure to infectious blood or to body fluids that contain blood, and the chronically infected person is central to the epidemiology of HBV transmission. All HBsAg-positive persons are infectious, but those who are also positive for hepatitis B e antigen (HBeAg) circulate HBV at high titers in their blood ( $10^{8-9}$  virions/mL) (26,27). With virus titers in blood this high, body fluids containing serum or blood also can contain high levels of HBV and are potentially infectious. Furthermore, HBV at titers of  $10^{2-3}$  virions/mL can be present on environmental surfaces in the absence of any visible blood and still result in transmission (28,29).

HBV is relatively stable in the environment and remains viable for at least 7 days on environmental surfaces at room temperature (29). HBsAg has been detected in dialysis centers on clamps, scissors, dialysis machine control knobs, and doorknobs (30). Thus, blood-contaminated surfaces that are not routinely cleaned and disinfected represent a reservoir for HBV transmission. Dialysis staff members can transfer virus to patients from contaminated surfaces by their hands or gloves or through use of contaminated equipment and supplies (30).

Most HBV infection outbreaks among hemodialysis patients were caused by cross-contamination to patients via a) environmental surfaces, supplies (e.g., hemostats, clamps), or equipment that were not routinely disinfected after each use; b) multiple dose medication vials and intravenous solutions that were not used exclusively for one patient; c) medications for injection that were prepared in areas adjacent to areas where blood samples were handled; and d) staff members who simultaneously cared for both HBV-infected and susceptible patients (21,31–35). Once the factors that promote HBV transmission among hemodialysis patients were identified, recommendations for control were published in 1977 (19). These recommendations included a) serologic surveillance of patients (and staff members) for HBV infection, including monthly testing of all susceptible patients for HBsAg; b) isolation of HBsAg-positive patients in a separate room; c) assignment of staff members to HBsAg-positive patients and not to HBV-susceptible patients during the same shift; d) assignment of dialysis equipment to HBsAg-positive patients that is not shared by HBV-susceptible patients; e) assignment of a supply tray to each patient (regardless of serologic status); f) cleaning and disinfection of nondisposable items (e.g., clamps, scissors) before use on another patient; g) glove use whenever any patient or hemodialysis equipment is touched and glove changes between each patient (and station); and h) routine cleaning and disinfection of equipment and environmental surfaces.

The segregation of HBsAg-positive patients and their equipment from HBV-susceptible patients resulted in 70%–80% reductions in incidence of HBV infection among hemodialysis patients (7,36–38). National surveillance data for 1976–1989 indicated that incidence of HBV infection was substantially lower in hemodialysis units

that isolated HBsAg-positive patients, compared with those that did not (7,10). The success of isolation practices in preventing transmission of HBV infection is linked to other infection control practices, including routine serological surveillance and routine cleaning and disinfection. Frequent serologic testing for HBsAg detects patients recently infected with HBV quickly so isolation procedures can be implemented before cross-contamination can occur. Environmental control by routine cleaning and disinfection procedures reduces the opportunity for cross-contamination, either directly from environmental surfaces or indirectly by hands of personnel.

Despite the current low incidence of HBV infection among hemodialysis patients, outbreaks continue to occur in chronic hemodialysis centers. Investigations of these outbreaks have documented that HBV transmission resulted from failure to use recommended infection control practices, including a) failure to routinely screen patients for HBsAg or routinely review results of testing to identify infected patients; b) assignment of staff members to the simultaneous care of infected and susceptible patients; and c) sharing of supplies, particularly multiple dose medication vials, among patients (21). In addition, few patients had received hepatitis B vaccine (21). National surveillance data have demonstrated that independent risk factors among chronic hemodialysis patients for acquiring HBV infection include the presence of  $\geq 1$  HBV-infected patient in the hemodialysis center who is not isolated, as well as a  $< 50\%$  hepatitis B vaccination rate among patients (15).

HBV infection among chronic hemodialysis patients also has been associated with hemodialysis provided in the acute-care setting (21,39). Transmission appeared to stem from chronically infected HBV patients who shared staff members, multiple dose medication vials, and other supplies and equipment with susceptible patients. These episodes were recognized when patients returned to their chronic hemodialysis units, and routine HBsAg testing was resumed. Transmission from HBV-infected chronic hemodialysis patients to patients undergoing hemodialysis for acute renal failure has not been documented, possibly because these patients are dialyzed for short durations and have limited exposure. However, such transmission could go unrecognized because acute renal failure patients are unlikely to be tested for HBV infection.

### ***Clinical Features and Natural History***

HBV causes both acute and chronic hepatitis. The incubation period ranges from 45–160 days (mean: 120 days), and the onset of acute disease is usually insidious. Infants, young children (aged  $< 10$  years), and immunosuppressed adults with newly acquired HBV infection are usually asymptomatic (40). When present, clinical symptoms and signs might include anorexia, malaise, nausea, vomiting, abdominal pain, and jaundice. Extrahepatic manifestations of disease (e.g., skin rashes, arthralgias, and arthritis) can also occur (41). The case fatality rate after acute hepatitis B is 0.5%–1%.

In adults with normal immune status, most (94%–98%) recover completely from newly acquired HBV infections, eliminating virus from the blood and producing neutralizing antibody that creates immunity from future infection (40,42). In immunosuppressed persons (including hemodialysis patients), infants, and young children, most newly acquired HBV infections result in chronic infection. Although the consequences of acute hepatitis B can be severe, most of the serious sequelae associated with the disease occur in persons in whom chronic infection develops. Although persons with chronic HBV infection are often asymptomatic, chronic liver disease develops in two-

thirds of these persons, and approximately 15%–25% die prematurely from cirrhosis or liver cancer (43–45).

Subtypes of HBV exist, and infection or immunization with one subtype confers immunity to all subtypes. However, reinfection or reactivation of latent HBV infection has been reported among certain groups of immunosuppressed patients, including those who have undergone renal transplant and those infected with human immunodeficiency virus (HIV) (46,47). These patients were positive for antibody to hepatitis B core antigen (anti-HBc), with or without antibody to HBsAg (anti-HBs), and subsequently developed detectable levels of HBsAg. The frequency with which this occurs is unknown.

Monotherapy with alpha interferon or lamivudine is approved by the U.S. Food and Drug Administration (FDA) to treat patients with chronic hepatitis B (48,49). Although the dosage of lamivudine should be modified based on creatinine clearance in patients with renal impairment, no additional dose modification is necessary after routine hemodialysis. The emergence of lamivudine-resistant variants has caused concern regarding long-term use of this drug.

### Screening and Diagnostic Tests

**Serologic Assays.** Several well-defined antigen-antibody systems are associated with HBV infection, including HBsAg and anti-HBs; hepatitis B core antigen (HBcAg) and anti-HBc; and HBeAg and antibody to HBeAg (anti-HBe). Serologic assays are commercially available for all of these except HBcAg because no free HBcAg circulates in blood. One or more of these serologic markers are present during different phases of HBV infection (Table 1) (42).

**TABLE 1. Interpretation of serologic test results for hepatitis B virus infection**

HBsAg*	Serologic Markers			Interpretation
	Total Anti-HBc†	IgM‡ Anti-HBc	Anti-HBs§	
–	–	–	–	Susceptible, never infected
+	–	–	–	Acute infection, early incubation**
+	+	+	–	Acute infection
–	+	+	–	Acute resolving infection
–	+	–	+	Past infection, recovered and immune
+	+	–	–	Chronic infection
–	+	–	–	False positive (i.e., susceptible), past infection, or “low-level” chronic infection
–	–	–	+	Immune if titer is $\geq 10$ mIU/mL

\* Hepatitis B surface antigen.

† Antibody to hepatitis B core antigen.

‡ Immunoglobulin M.

§ Antibody to hepatitis B surface antigen.

\*\* Transient HBsAg positivity (lasting  $\leq 18$  days) might be detected in some patients during vaccination.

The presence of HBsAg is indicative of ongoing HBV infection and potential infectiousness. In newly infected persons, HBsAg is present in serum 30–60 days after exposure to HBV and persists for variable periods. Transient HBsAg positivity (lasting  $\leq 18$  days) can be detected in some patients during vaccination (50,51). Anti-HBc develops in all HBV infections, appearing at onset of symptoms or liver test abnormalities in acute HBV infection, rising rapidly to high levels, and persisting for life. Acute or recently acquired infection can be distinguished by presence of the immunoglobulin M (IgM) class of anti-HBc, which persists for approximately 6 months.

In persons who recover from HBV infection, HBsAg is eliminated from the blood, usually in 2–3 months, and anti-HBs develops during convalescence. The presence of anti-HBs indicates immunity from HBV infection. After recovery from natural infection, most persons will be positive for both anti-HBs and anti-HBc, whereas only anti-HBs develops in persons who are successfully vaccinated against hepatitis B. Persons who do not recover from HBV infection and become chronically infected remain positive for HBsAg (and anti-HBc), although a small proportion (0.3% per year) eventually clear HBsAg and might develop anti-HBs (45).

In some persons, the only HBV serologic marker detected is anti-HBc (i.e., isolated anti-HBc). Among most asymptomatic persons in the United States tested for HBV infection, an average of 2% (range:  $<0.1\%$ –6%) test positive for isolated anti-HBc (52); among injecting-drug users, however, the rate is 24% (53). In general, the frequency of isolated anti-HBc is directly related to the frequency of previous HBV infection in the population and can have several explanations. This pattern can occur after HBV infection among persons who have recovered but whose anti-HBs levels have waned or among persons who failed to develop anti-HBs. Persons in the latter category include those who circulate HBsAg at levels not detectable by current commercial assays. However, HBV DNA has been detected in  $<10\%$  of persons with isolated anti-HBc, and these persons are unlikely to be infectious to others except under unusual circumstances involving direct percutaneous exposure to large quantities of blood (e.g., transfusion) (54). In most persons with isolated anti-HBc, the result appears to be a false positive. Data from several studies have demonstrated that a primary anti-HBs response develops in most of these persons after a three-dose series of hepatitis B vaccine (55,56). No data exist on response to vaccination among hemodialysis patients with this serologic pattern.

A third antigen, HBeAg, can be detected in serum of persons with acute or chronic HBV infection. The presence of HBeAg correlates with viral replication and high levels of virus (i.e., high infectivity). Anti-HBe correlates with the loss of replicating virus and with lower levels of virus. However, all HBsAg-positive persons should be considered potentially infectious, regardless of their HBeAg or anti-HBe status.

**Nucleic Acid Detection.** HBV infection can be detected using qualitative or quantitative tests for HBV DNA. These tests are not FDA-approved and are most commonly used for patients being managed with antiviral therapy (49,57).

### ***Hepatitis B Vaccine***

Hepatitis B vaccine has been recommended for both hemodialysis patients and staff members since the vaccine became available in 1982 (20). By 1999, a total of 55% of patients and 88% of staff members had been vaccinated (18) (CDC, unpublished data, 2001). Two types of vaccine have been licensed and used in the United States: plasma-derived and recombinant. Plasma-derived vaccine is no longer available in the United

States, but is produced in several countries and used in many immunization programs worldwide. Recombinant vaccines available in the United States are Recombivax HB™ (Merck & Company, Inc., West Point, Pennsylvania) and Engerix-B® (SmithKline Beecham Biologicals, Philadelphia, Pennsylvania). Recombivax HB™ contains 10–40 µg of HBsAg protein per mL, whereas Engerix-B® contains 20 µg/mL.

Primary vaccination comprises three intramuscular doses of vaccine, with the second and third doses given 1 and 6 months, respectively, after the first. An alternative schedule of four doses given at 0, 1, 2, and 12 months to persons with normal immune status or at 0, 1, 2, and 6 months to hemodialysis patients has been approved for Engerix-B®.

**Immunogenicity.** The recommended primary series of hepatitis B vaccine induces a protective anti-HBs response (defined as  $\geq 10$  milli-International Units [mIU]/mL) in 90%–95% of adults with normal immune status. The major determinant of vaccine response is age, with the proportion of persons developing a protective antibody response declining to 84% among adults aged  $>40$  years and to 75% by age 60 years (58,59). Other host factors that contribute to decreased immunogenicity include smoking, obesity, and immune suppression. Compared with adults with normal immune status, the proportion of hemodialysis patients who develop a protective antibody response after vaccination (with higher dosages) is lower. For those who receive the three-dose schedule, the median is 64% (range: 34%–88%) (60–65), and for those who receive the four-dose schedule, the median is 86% (range: 40%–98%) (66–72). Limited data indicate that concurrent infection with HCV does not interfere with development of protective levels of antibody after vaccination, although lower titers of anti-HBs have been reported after vaccination of HCV-positive patients compared with HCV-negative patients (65,73–75).

Some studies have demonstrated that higher antibody response rates could be achieved by vaccinating patients with chronic renal failure before they become dialysis dependent, particularly patients with mild or moderate renal failure. After vaccination with four 20 µg doses of recombinant vaccine, a protective antibody response developed in 86% of predialysis adult patients with serum creatinine levels  $\leq 4.0$  mg/dl (mean: 2.0 mg/dl) compared with 37% of those with serum creatinine levels  $>4.0$  mg/dl (mean: 9.5 mg/dl), only 12% of whom were predialysis patients (76). In an earlier study, a lower response to recombinant vaccine among predialysis patients was reported, possibly because patients with more severe renal failure were included (77,78).

Although no data exist on the response of pediatric hemodialysis patients to vaccination with standard pediatric doses, 75%–97% of those who received higher dosages (20 µg) on either the three- or four-dose schedule developed protective levels of anti-HBs (79–81). In the one study that evaluated vaccine response among children with chronic renal failure before they became dialysis dependent, high response rates were achieved after four-20 µg doses in both predialysis and dialysis-dependent patients, although predialysis patients had higher peak antibody titers (82).

**Vaccine Efficacy.** For persons with normal immune status, controlled clinical trials have demonstrated that protection from acute and chronic HBV infection is virtually complete among those who develop a protective antibody response after vaccination (83,84). Among hemodialysis patients, controlled clinical trials conducted in other countries demonstrated efficacy of 53%–78% after preexposure immunization (85,86). However, no efficacy was demonstrated in the one trial performed in the United States (62). When the latter trial was designed, the sample size was calculated based on an annual

incidence rate among susceptible patients of 13.8% (i.e., the rate observed during 1976–1979, the period before the start of the trial). However, by the time the trial was conducted, the incidence rate had declined by >60%, and the sample size was inadequate for detecting a difference in infection rates between vaccinated and placebo groups. Although efficacy was not demonstrated in this study, no infections occurred among persons who developed and maintained protective levels of anti-HBs.

Furthermore, since the hepatitis B vaccine became available, no HBV infections have been reported among vaccinated hemodialysis patients who maintained protective levels of anti-HBs. This observation has been particularly striking during HBV infection outbreaks in this setting (21). In addition, a case-control study indicated that the risk for HBV infection was 70% lower among hemodialysis patients who had been vaccinated (87). Thus, most hemodialysis patients can be protected from hepatitis B by vaccination, and maintaining immunity among these patients reduces the frequency and costs of serologic screening (88).

**Revaccination of Nonresponders.** Among persons who do not respond to the primary three-dose series of hepatitis B vaccine, 25%–50% of those with normal immune status respond to one additional vaccine dose, and 50%–75% respond to three additional doses (59,84). A revaccination regimen that includes serologic testing after one or two additional doses of vaccine appears to be no more cost-effective than serologic testing performed after all three additional doses (89). For persons found to be nonresponders after six doses of vaccine, no data exist to indicate that additional doses would induce an antibody response. Few studies have been conducted of the effect of revaccination among hemodialysis patients who do not respond to the primary vaccine series. Response rates to revaccination varied from 40%–50% after two or three additional 40 µg intramuscular doses to 64% after four additional 10 µg intramuscular doses (69,70,90–94).

**Antibody Persistence.** Among adults with normal immune status who responded to a primary vaccine series with a protective antibody level, antibody remained above protective levels in 40%–87% of persons after 9–15 years (95–98). Only short-term data are available for hemodialysis patients. Among adults who responded to the primary vaccination series, antibody remained detectable for 6 months in 80%–100% (median: 100%) of persons and for 12 months in 58%–100% (median: 70%) (61,64–69,71,85,99–103). Among successfully immunized hemodialysis patients whose antibody titers subsequently declined below protective levels, limited data indicate that virtually all respond to a booster dose (75).

**Duration of Vaccine-Induced Immunity.** Among persons with normal immune status who respond to the primary series of hepatitis B vaccine, protection against hepatitis B persists even when antibody titers become undetectable (97). However, among hemodialysis patients who respond to the vaccine, protection against hepatitis B is not maintained when antibody titers fall below protective levels. In the U.S. vaccine efficacy trial, three hemodialysis patients who responded to the primary vaccination series developed HBV infection (62). One had received a kidney transplant 6 months before onset of infection, and anti-HBs had declined to borderline protective levels in the other two persons. In all three patients, infection resolved.

**Alternative Routes of Administration.** Among adults with normal immune status, intradermal administration of low doses of hepatitis B vaccine results in lower seroconversion rates (55%–81%) (104–106), and no data exist on long-term protection from this route of administration. Among infants and children, intradermal vaccination



results in poor immunogenicity. Data are insufficient to evaluate alternative routes (e.g., intradermal) for vaccination among hemodialysis patients.

## Hepatitis C Virus Infection

### *Epidemiology*

**Incidence and Prevalence.** Data are limited on incidence of HCV infection among chronic hemodialysis patients. During 1982–1997, the incidence of non-A, non-B hepatitis among patients reported to CDC's national surveillance system decreased from 1.7% to 0.2% (18). The validity of these rates is uncertain because of inherent difficulties in diagnosing non-A, non-B hepatitis and probable variability in the application of diagnostic criteria by different dialysis centers. However, the downward trend can partially be explained by a decline in the rate of transfusion-associated disease after 1985 (107,108).

Since 1990, limited data from U.S. studies using testing for antibody to HCV (anti-HCV) to evaluate the incidence of HCV infection have reported annual rates of 0.73%–3% among hemodialysis patients (109,110). None of the patients who seroconverted had received transfusions in the interim or were injecting-drug users.

During 1992–1999, national surveillance data indicated that the proportion of centers that tested patients for anti-HCV increased from 22% to 56% (18) (CDC, unpublished data, 2001). In 1999, nationwide prevalence of anti-HCV was 8.9%, with some centers reporting prevalences >40% (CDC, unpublished data, 2001). Other studies of hemodialysis patients in the United States have reported anti-HCV prevalences of 10%–36% among adults (109,111,112) and 18.5% among children (113).

**Transmission.** HCV is most efficiently transmitted by direct percutaneous exposure to infectious blood, and like HBV, the chronically infected person is central to the epidemiology of HCV transmission. Risk factors associated with HCV infection among hemodialysis patients include history of blood transfusions, the volume of blood transfused, and years on dialysis (114). The number of years on dialysis is the major risk factor independently associated with higher rates of HCV infection. As the time patients spent on dialysis increased, their prevalence of HCV infection increased from an average of 12% for patients receiving dialysis <5 years to an average of 37% for patients receiving dialysis ≥5 years (109,112,115).

These studies, as well as investigations of dialysis-associated outbreaks of hepatitis C, indicate that HCV transmission most likely occurs because of inadequate infection control practices. During 1999–2000, CDC investigated three outbreaks of HCV infection among patients in chronic hemodialysis centers (CDC, unpublished data, 1999 and 2000). In two of the outbreaks, multiple transmissions of HCV occurred during periods of 16–24 months (attack rates: 6.6%–17.5%), and seroconversions were associated with receiving dialysis immediately after a chronically infected patient. Multiple opportunities for cross-contamination among patients were observed, including a) equipment and supplies that were not disinfected between patient use; b) use of common medication carts to prepare and distribute medications at patients' stations; c) sharing of multiple dose medication vials, which were placed at patients' stations on top of hemodialysis machines; d) contaminated priming buckets that were not routinely changed or cleaned and disinfected between patients; e) machine surfaces that were not routinely cleaned and disinfected between patients; and f) blood spills that were

not cleaned up promptly. In the third outbreak, multiple new infections clustered at one point in time (attack rate: 27%), suggesting a common exposure event. Although the specific results of this investigation are pending, multiple opportunities for cross-contamination from chronically infected patients also were observed in this unit. In particular, supply carts were moved from one station to another and contained both clean supplies and blood-contaminated items, including small biohazard containers, sharps disposal boxes, and used vacutainers containing patients' blood.

### ***Clinical Features and Natural History***

HCV causes both acute and chronic hepatitis. The incubation period ranges from 14–180 days (average: 6–7 weeks) (116). Persons with newly acquired (acute) HCV infection typically are either asymptomatic or have a mild clinical illness. The course of acute hepatitis C is variable, although elevations in serum alanine aminotransferase (ALT) levels, often in a fluctuating pattern, are the most characteristic feature. Fulminant hepatic failure after acute hepatitis C is rare.

Most (average: 94%) hemodialysis patients with newly acquired HCV infection have elevated serum ALT levels (117–121). Elevations in serum ALT levels often precede anti-HCV seroconversion. Among prospectively followed transfusion recipients who developed acute HCV infection, elevated ALT levels preceded anti-HCV seroconversion (as measured by second generation assays) in 59%, and anti-HCV was detectable in most patients (78%) within 5 weeks after their first ALT elevation (122). However, elevations in ALT or aspartate aminotransferase (AST) levels can occur that are not related to viral hepatitis, and compared with ALT, AST is a less specific indicator of HCV-related liver disease among hemodialysis patients. In a recent outbreak investigation, only 28% of 25 hemodialysis patients with newly observed elevations in AST levels tested anti-HCV positive (CDC, unpublished data, 1999).

After acute HCV infection, 15%–25% of persons with normal immune status appear to resolve their infection without sequelae as defined by sustained absence of HCV RNA in serum and normalization of ALT (123). In some persons, ALT levels normalize, suggesting full recovery, but this is frequently followed by ALT elevations that indicate progression to chronic disease. Chronic HCV infection develops in most infected persons (75%–85%). Of persons with chronic HCV infection, 60%–70% have persistent or fluctuating ALT elevations, indicating active liver disease (123). Although similar rates of chronic liver disease have been observed among HCV-infected chronic hemodialysis patients (based on liver biopsy results), these patients might be less likely to have biochemical evidence of active liver disease (124). In seroprevalence studies of chronic hemodialysis patients, ALT elevations were reported in a median of 33.9% (range: 6%–73%) of patients who tested positive for anti-HCV (117,124–136).

No clinical or epidemiologic features among patients with acute infection have been reported to be predictive of either persistent infection or chronic liver disease. Most studies have reported that cirrhosis develops in 10%–20% of persons who have had chronic hepatitis C for 20–30 years, and hepatocellular carcinoma in 1%–5% (123). Extrahepatic manifestations of chronic HCV infection are considered to be of immunologic origin and include cryoglobulinemia, membranoproliferative glomerulonephritis, and porphyria cutanea tarda (137).

At least six different genotypes and >90 subtypes of HCV exist, with genotype 1 being the most common in the United States (138,139). Unlike HBV, infection with one

HCV genotype or subtype does not protect against reinfection or superinfection with other HCV strains (139).

Alpha interferon alone or in combination with ribavirin is FDA-approved for the treatment of chronic hepatitis C (48,140,141). Combination therapy should be used with caution in patients with creatinine clearance <50 mL/minute and generally is contraindicated in patients with renal failure (141,142). Interferon monotherapy results in low sustained virologic response rates (141,142).

### **Screening and Diagnostic Tests**

**Serologic Assays.** The only FDA-approved tests for diagnosis of HCV infection are those that measure anti-HCV and include enzyme immunoassays (EIAs) and a supplemental recombinant immunoblot assay (RIBA™) (116). These tests detect anti-HCV in  $\geq 97\%$  of infected persons, but do not distinguish between acute, chronic, or resolved infection. The average time from exposure to seroconversion is 8–9 weeks (122). Anti-HCV can be detected in 80% of patients within 15 weeks after exposure, in  $\geq 90\%$  within 5 months, and in  $\geq 97\%$  within 6 months (122,143). In rare instances, seroconversion can be delayed until 9 months after exposure (143,144). Anti-HCV persists indefinitely in most persons, but does not protect against reinfection.

As with any screening test, the positive predictive value of EIAs for anti-HCV is directly related to the prevalence of infection in the population and is low in populations with an HCV-infection prevalence <10% (145,146). Supplemental testing with a more specific assay (i.e., RIBA™) of a specimen with a positive anti-HCV result by EIA prevents reporting of false-positive results, particularly in settings where asymptomatic persons are being tested. Results of seroprevalence studies among chronic hemodialysis patients have indicated that 57%–100% of EIA positive results were RIBA™ positive (124,126,128,133,135,147–152), and 53%–100% were HCV RNA positive by reverse transcriptase polymerase chain reaction (RT-PCR) testing (117,127,129,134,135).

**Nucleic Acid Detection.** The diagnosis of HCV infection also can be made by qualitatively detecting HCV RNA using gene amplification techniques (e.g., RT-PCR) (116). HCV RNA can be detected in serum or plasma within 1–2 weeks after exposure and weeks before onset of ALT elevations or the appearance of anti-HCV. In rare instances, detection of HCV RNA might be the only evidence of HCV infection. Although a median of 3.4% (range: 0%–28%) of chronic hemodialysis patients who tested anti-HCV negative were HCV RNA positive, this might be an overestimate because follow-up samples to detect possible antibody seroconversions were not obtained on these patients (117,118,126–128,130,131,133,134,148–154).

Although not FDA-approved, RT-PCR assays for HCV infection are used commonly in clinical practice and are commercially available. Most RT-PCR assays have a lower limit of detection of 100–1,000 viral genome copies per mL. With adequate optimization of RT-PCR assays, 75%–85% of persons who are positive for anti-HCV and >95% of persons with acute or chronic hepatitis C will test positive for HCV RNA. Some HCV-infected persons might be only intermittently HCV RNA positive, particularly those with acute hepatitis C or with end-stage liver disease caused by hepatitis C. To minimize false-negative results, blood samples collected for RT-PCR should not contain heparin, and serum must be separated from cellular components within 2–4 hours after collection and preferably stored frozen at -20 C or -70 C (155). If shipping is required, frozen samples should be protected from thawing. Because of assay variability,

rigorous quality assurance and control should be in place in clinical laboratories performing this assay, and proficiency testing is recommended.

Quantitative assays for measuring the concentration (i.e., titer) of HCV RNA have been developed and are available from commercial laboratories (156). These assays also are not FDA-approved and are less sensitive than qualitative RT-PCR assays (157). Quantitative assays should not be used as a primary test to confirm or exclude the diagnosis of HCV infection or to monitor the endpoint of treatment, and sequential measurement of HCV RNA levels has not proven useful in managing patients with hepatitis C.

## **Other Bloodborne Viruses**

### ***Hepatitis Delta Virus Infection***

Delta hepatitis is caused by the hepatitis delta virus (HDV), a defective virus that causes infection only in persons with active HBV infection. The prevalence of HDV infection is low in the United States, with rates of <1% among HBsAg-positive persons in the general population and  $\geq 10\%$  among HBsAg-positive persons with repeated percutaneous exposures (e.g., injecting-drug users, persons with hemophilia) (158). Areas of the world with high endemic rates of HDV infection include southern Italy, parts of Africa, and the Amazon Basin.

Few data exist on the prevalence of HDV infection among chronic hemodialysis patients, and only one transmission of HDV between such patients has been reported in the United States (159). In this episode, transmission occurred from a patient who was chronically infected with HBV and HDV to an HBsAg-positive patient after a massive bleeding incident; both patients received dialysis at the same station.

HDV infection occurs either as a co-infection with HBV or as a superinfection in a person with chronic HBV infection. Co-infection usually resolves, but superinfection frequently results in chronic HDV infection and severe disease. High mortality rates are associated with both types of infection. A serologic test that measures total antibody to HDV (anti-HDV) is commercially available.

### ***Human Immunodeficiency Virus Infection***

During 1985–1999, the percentage of U.S. hemodialysis centers that reported providing chronic hemodialysis for patients with HIV infection increased from 11% to 39%, and the proportion of hemodialysis patients with known HIV infection increased from 0.3% to 1.4% (18) (CDC, unpublished data, 2001).

HIV is transmitted by blood and other body fluids that contain blood. No patient-to-patient transmission of HIV has been reported in U.S. hemodialysis centers. However, such transmission has been reported in other countries; in one case, HIV transmission was attributed to mixing of reused access needles and inadequate disinfection of equipment (160).

HIV infection is usually diagnosed with assays that measure antibody to HIV, and a repeatedly positive EIA test should be confirmed by Western blot or another confirmatory test. Antiretroviral therapies for HIV-infected hemodialysis patients are commonly used and appear to be improving survival rates among this population. However, hepatotoxicity associated with certain protease inhibitors might limit the use of these drugs, especially in patients with underlying liver dysfunction (161).

## Bacterial Infections

### *Epidemiology*

**Disease Burden.** The annual mortality rate among hemodialysis patients is 23%, and infections are the second most common cause, accounting for 15% of deaths (1). Septicemia (10.9% of all deaths) is the most common infectious cause of mortality. In various studies evaluating rates of bacterial infections in hemodialysis outpatients, bacteremia occurred in 0.63%–1.7% of patients per month and vascular access infections (with or without bacteremia) in 1.3%–7.2% of patients per month (162–170). National surveillance data indicated that 4%–5% of patients received intravenous vancomycin during a 1-month period (and additional patients received other antimicrobials) (18). Although data on vancomycin use can be used to derive an estimate of the prevalence of suspected infections, the proportion of patients receiving antimicrobials who would fit a formal case definition for bacterial infection is unknown.

**Infection Sites.** In a study of 27 French hemodialysis centers, 28% of 230 infections in hemodialysis patients involved the vascular access, whereas 25% involved the lung, 23% the urinary tract, 9% the skin and soft tissues, and 15% other or unknown sites (165). Thirty-three percent of infections involved either the vascular access site or were bacteremias of unknown origin, many of which might have been caused by occult access infections. Thus, the vascular access site was the most common site for infection, but accounted for only one-third of infections. However, access site infections are particularly important because they can cause disseminated bacteremia or loss of the vascular access.

**Vascular Access Infections.** Vascular access infections are caused (in descending order of frequency) by *S. aureus*, coagulase-negative staphylococci (CNS), gram-negative bacilli, nonstaphylococcal gram-positive cocci (including enterococci), and fungi (171). The proportion of infections caused by CNS is higher among patients dialyzed through catheters than among patients dialyzed through fistulas or grafts.

The primary risk factor for access infection is access type, with catheters having the highest risk for infection, grafts intermediate, and native arteriovenous (AV) fistulas the lowest (168). Other potential risk factors for vascular access infections include a) location of the access in the lower extremity; b) recent access surgery; c) trauma, hematoma, dermatitis, or scratching over the access site; d) poor patient hygiene; e) poor needle insertion technique; f) older age; g) diabetes; h) immunosuppression; and i) iron overload (164,167,172–175).

**Transmission.** Bacterial pathogens causing infection can be either exogenous (i.e., acquired from contaminated dialysis fluids or equipment) or endogenous (i.e., caused by invasion of bacteria present in or on the patient). Exogenous pathogens have caused numerous outbreaks, most of which resulted from inadequate dialyzer reprocessing procedures (e.g., contaminated water or inadequate disinfectant) or inadequate treatment of municipal water for use in dialysis. During 1995–1997, four outbreaks were traced to contamination of the waste drain port on one type of dialysis machine (176). Recommendations to prevent such outbreaks are published elsewhere (171).

Contaminated medication vials also are a potential source of bacterial infection for patients. In 1999, an outbreak of *Serratia liquefaciens* bloodstream infections and pyrogenic reactions among hemodialysis patients was traced to contamination of vials of erythropoietin. These vials, which were intended for single use, were contaminated by

repeated puncture to obtain additional doses and by pooling of residual medication into a common vial (177).

Endogenous pathogens first colonize the patient and later cause infection. Colonization means that microorganisms have become resident in or on the body (e.g., in the nares or stool); a culture from the site is positive, but no symptoms or signs of infection exist. Colonization with potentially pathogenic microorganisms, often unknown to staff members, is common in patients with frequent exposure to hospitals and other health-care settings. Colonization most often occurs when microorganisms are transmitted from a colonized or infected source patient to another patient on the hands of health-care workers who do not comply with infection control precautions. Less commonly, contamination of environmental surfaces (e.g., bed rails, countertops) plays a role (178).

Infection occurs when microorganisms invade the body, damaging tissue and causing signs or symptoms of infection, and is aided by invasive devices (e.g., the hemodialysis vascular access). Evidence exists that when prevalence of colonization in a population is less frequent, infection in that population will also be less frequent, and infection control recommendations for hemodialysis units are designed to prevent colonization (179). Additional measures designed to prevent infection from colonizing organisms (e.g., using aseptic technique during vascular access) are presented elsewhere (180).

### ***Antimicrobial Resistance***

Antimicrobial-resistant bacteria are more common in patients with severe illness, who often have had multiple hospitalizations or surgical procedures, and in those who have received prolonged courses of antimicrobial agents. In health-care settings, including hemodialysis centers, such patients can serve as a source for transmission.

Clinically important drug-resistant bacteria that commonly cause health-care-associated infections include MRSA, methicillin-resistant CNS, VRE, and multidrug-resistant gram negative rods, including strains of *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia*, and *Acinetobacter* species, some of which are resistant to all available antimicrobials. In addition, strains of *S. aureus* with intermediate resistance to vancomycin and other glycopeptide antibiotics have recently been reported; these strains are called vancomycin-intermediate *S. aureus* (VISA) or glycopeptide-intermediate *S. aureus* (GISA) (181,182). Intermediate resistance to vancomycin is reported even more frequently among CNS (183,184).

Hemodialysis patients have played a prominent role in the epidemic of vancomycin resistance. In 1988, a renal unit in London, England, reported one of the first cases of VRE (185). In three studies, 12%–22% of hospitalized patients infected or colonized with VRE were receiving hemodialysis (178,186,187). Furthermore, three of the first five patients identified with VISA (or GISA) were on chronic hemodialysis, and one had received acute dialysis (182).

Prevalence of VRE has increased rapidly at U.S. hospitals; among intensive care unit patients with nosocomial infections reported to the National Nosocomial Infections Surveillance (NNIS) system, the percentage of enterococcal isolates resistant to vancomycin increased from 0.5% in 1989 to 25.2% in 1999 (23) (CDC, unpublished data, 2000). This increase is attributable to patient-to-patient transmission in health-care settings and transmission of resistant genes among previously susceptible enterococci. Once vancomycin resistance has been transferred to a patient, antimicrobials select for resistant organisms, causing them to increase in number relative to suscep-

tible organisms. Prevalence of VRE colonization among patients varies in different health-care settings; in hemodialysis centers, the reported prevalence in stool samples ranged from 1% to 9% (188,189). In one center with a prevalence of 9%, three patients developed VRE infections in 1 year (188).

### ***Vancomycin Use***

Dialysis patients have played a prominent role in the epidemic of vancomycin resistance because this drug is used commonly in these patients, in part because vancomycin can be conveniently administered to patients when they come in for hemodialysis treatments. However, two studies indicate that cefazolin, a first-generation cephalosporin, could be substituted for vancomycin in many patients (190,191). One of these studies reported that many pathogens causing infections in hemodialysis patients are susceptible to cefazolin (190), and both studies reported therapeutic cefazolin blood levels 48–72 hours after dosing, making in-center administration three times a week after dialysis feasible.

## **Equipment, Supplies, and Environmental Surfaces**

The hemodialysis machine and its components also can be vehicles for patient-to-patient transmission of bloodborne viruses and pathogenic bacteria (24,192). The external surfaces of the machine are the most likely sources for contamination. These include not only frequently touched surfaces (e.g., the control panel), but also attached waste containers used during the priming of the dialyzers, blood tubing draped or clipped to waste containers, and items placed on tops of machines for convenience (e.g., dialyzer caps and medication vials).

### ***Sterilization, Disinfection, and Cleaning***

A sterilization procedure kills all microorganisms, including highly resistant bacterial spores (24). Sterilization procedures are most commonly accomplished by steam or ethylene oxide gas. For products that are heat sensitive, an FDA-cleared liquid chemical sterilant can be used with a long exposure time (i.e., 3–10 hours).

High-level disinfection kills all viruses and bacteria, but not high numbers of bacterial spores. High-level disinfection can be accomplished by heat pasteurization or, more commonly, by an FDA-cleared chemical sterilant, with an exposure time of 12–45 minutes. Sterilants and high-level disinfectants are designed to be used on medical devices, not environmental surfaces. Intermediate-level disinfection kills bacteria and most viruses and is accomplished by using a tuberculocidal “hospital disinfectant” (a term used by the U.S. Environmental Protection Agency [EPA] in registering germicides) or a 1:100 dilution of bleach (300–600 mg/L free chlorine). Low-level disinfection kills most bacteria and is accomplished by using general purpose disinfectants. Intermediate and low-level disinfectants are designed to be used on environmental surfaces; they also can be used on noncritical medical devices, depending on the design and labeling claim.

Cleaning eliminates dirt and some bacteria and viruses and is accomplished by using a detergent or detergent germicide. Antiseptics (e.g., formulations with povidone-iodine, hexachlorophene, or chlorhexidene) are designed for use on skin and tissue and should not be used on medical equipment or environmental surfaces.

Regardless of the procedure used, cleaning with a germicidal detergent before disinfection (or sterilization) is essential to remove organic material (e.g., blood, mucous, or feces), dirt, or debris. The presence of such material protects microorganisms from the sterilization or disinfection process by physically blocking or inactivating the disinfectant or sterilant.

The choice of what procedure or which chemical germicide to use for medical devices, instruments, and environmental surfaces depends on several factors, including the need to maintain the structural integrity and function of the item and how the item will be used. Three general categories of use for medical items are recognized, each of which require different levels of sterilization or disinfection (193). These categories are a) critical, which includes items introduced directly into the bloodstream or normally sterile areas of the body (e.g., needles, catheters, hemodialyzers, blood tubing); b) semicritical, which includes equipment that comes in contact with intact mucous membranes (e.g., fiberoptic endoscopes, glass thermometers); and c) noncritical, which includes equipment that touches only intact skin (e.g., blood pressure cuffs). Semicritical items are not generally used in dialysis units.

**Internal Pathways of Hemodialysis Machines.** In single-pass hemodialysis machines, the internal fluid pathways are not subject to contamination with blood. If a dialyzer leak occurs, dialysis fluid might become contaminated with blood, but this contaminated fluid is discarded through a drain and does not return to the dialysis machine to contaminate predialyzer surfaces. For dialysis machines that use a dialysate recirculating system (e.g., some ultrafiltration control machines and those that regenerate the dialysate), a blood leak in a dialyzer could contaminate the internal pathways of the machine, which could in turn contaminate the dialysis fluid of subsequent patients (192). However, procedures normally practiced after each use (i.e., draining the dialysis fluid and rinsing and disinfecting the machine) will reduce the level of contamination to below infectious levels. In addition, an intact dialyzer membrane will not allow passage of bacteria or viruses (24).

Pressure transducer filter protectors are used primarily to prevent contamination and preserve the functioning of the pressure monitoring (i.e., arterial, venous, or both) components of the hemodialysis machine. Hemodialysis machines usually have both external (typically supplied with the blood tubing set) and internal protectors, with the internal protector serving as a backup in case the external transducer protector fails. Failure to use an external protector or to replace the protector when it becomes contaminated (i.e., wetted with saline or blood) can result in contamination of the internal transducer protector, which in turn could allow transmission of bloodborne pathogens (24). However, no epidemiologic evidence exists that contamination of the internal transducer protector caused by failure of the external transducer protector has led to either mixing of blood or the transmission of bloodborne agents.

**Dialyzer Reprocessing.** Approximately 80% of U.S. chronic hemodialysis centers reprocess (i.e., reuse) dialyzers for the same patient (18), and guidelines for reprocessing have been published elsewhere (see Suggested Readings). Although outbreaks of bacterial infections and pyrogenic reactions have occurred because of inadequate reprocessing procedures and failure to maintain standards for water quality, reuse has not been associated with transmission of bloodborne viruses. Any theoretical risk for HBV transmission from reuse of dialyzers would primarily affect staff members who handle these dialyzers. Although no increase in HBV (or HCV) infection among staff



members who work in such centers has been reported, many centers do not reuse dialyzers from HBsAg-positive patients (24).

## **Infection Control Precautions for Outpatient Hemodialysis Settings Compared with Inpatient Hospital Settings**

Contact transmission is the most important route by which pathogens are transmitted in health-care settings, including hemodialysis units. Contact transmission occurs most commonly when microorganisms from a patient are transferred to the hands of a health-care worker who does not comply with infection control precautions, then touches another patient. Less commonly, environmental surfaces (e.g., bed rails, countertops) become contaminated and serve as an intermediate reservoir for pathogens; transmission can occur when a worker touches the surface then touches a patient or when a patient touches the surface.

In the hemodialysis setting, contact transmission plays a major role in transmission of bloodborne pathogens. If a health-care worker's hands become contaminated with virus-infected blood from one patient, the worker can transfer the virus to a second patient's skin or blood line access port, and the virus can be inoculated into that patient when the skin or access port is punctured with a needle.

Contact transmission can be prevented by hand hygiene (i.e., hand washing or use of a waterless hand rub), glove use, and disinfection of environmental surfaces. Of these, hand hygiene is the most important. In addition, nonsterile disposable gloves provide a protective barrier for workers' hands, preventing them from becoming soiled or contaminated, and reduce the likelihood that microorganisms present on the hands of personnel will be transmitted to patients. However, even with glove use, hand washing is needed because pathogens deposited on the outer surface of gloves can be detected on hands after glove removal, possibly because of holes or defects in the gloves, leakage at the wrist, or contamination of hands during glove removal (194).

Standard Precautions are the system of infection control precautions recommended for the inpatient hospital setting (195). Standard Precautions are used on all patients and include use of gloves, gown, or mask whenever needed to prevent contact of the health-care worker with blood, secretions, excretions, or contaminated items.

In addition to Standard Precautions, more stringent precautions are recommended for hemodialysis units because of the increased potential for contamination with blood and pathogenic microorganisms (see Infection Control Practices Recommended for Hemodialysis Units). For example, infection control practices for hemodialysis units restrict the use of common supplies, instruments, medications, and medication trays and prohibit the use of a common medication cart.

For certain patients, including those infected or colonized with MRSA or VRE, contact precautions are used in the inpatient hospital setting. Contact precautions include a) placing the patient in a single room or with another patient infected or colonized with the same organism; b) using gloves whenever entering the patient's room; and c) using a gown when entering the patient's room if the potential exists for the worker's clothing to have substantial contact with the patient, environmental surfaces, or items in the patient's room. Workers also should wear a gown if the patient has diarrhea, an ileostomy, a colostomy, or wound drainage not contained by a dressing.

However, contact precautions are not recommended in hemodialysis units for patients infected or colonized with pathogenic bacteria for several reasons. First, although

contact transmission of pathogenic bacteria is well-documented in hospitals, similar transmission has not been well-documented in hemodialysis centers. Transmission might not be apparent in dialysis centers, possibly because it occurs less frequently than in acute-care hospitals or results in undetected colonization rather than overt infection. Also, because dialysis patients are frequently hospitalized, determining whether transmission occurred in the inpatient or outpatient setting is difficult. Second, contamination of the patient's skin, bedclothes, and environmental surfaces with pathogenic bacteria is likely to be more common in hospital settings (where patients spend 24 hours a day) than in outpatient hemodialysis centers (where patients spend approximately 10 hours a week). Third, the routine use of infection control practices recommended for hemodialysis units, which are more stringent than the Standard Precautions routinely used in hospitals, should prevent transmission by the contact route.

## RECOMMENDATIONS

### Rationale

Preventing transmission among chronic hemodialysis patients of bloodborne viruses and pathogenic bacteria from both recognized and unrecognized sources of infection requires implementation of a comprehensive infection control program. The components of such a program include infection control practices specifically designed for the hemodialysis setting, including routine serologic testing and immunization, surveillance, and training and education (Box).

The infection control practices recommended for hemodialysis units will reduce opportunities for patient-to-patient transmission of infectious agents, directly or indirectly via contaminated devices, equipment and supplies, environmental surfaces, or hands of personnel. These practices should be carried out routinely for all patients in the chronic hemodialysis setting because of the increased potential for blood contamination during hemodialysis and because many patients are colonized or infected with pathogenic bacteria. Such practices include additional measures to prevent HBV transmission because of the high titer of HBV and its ability to survive on environmental surfaces. For patients at increased risk for transmission of pathogenic bacteria, includ-

### **BOX. Components of a comprehensive infection control program to prevent transmission of infections among chronic hemodialysis patients**

- **Infection control practices for hemodialysis units.**
  - Infection control precautions specifically designed to prevent transmission of bloodborne viruses and pathogenic bacteria among patients.
  - Routine serologic testing for hepatitis B virus and hepatitis C virus infections.
  - Vaccination of susceptible patients against hepatitis B.
  - Isolation of patients who test positive for hepatitis B surface antigen.
- **Surveillance for infections and other adverse events.**
- **Infection control training and education.**

ing antimicrobial-resistant strains, additional precautions also might be necessary in some circumstances. Furthermore, surveillance for infections and other adverse events is required to monitor the effectiveness of infection control practices, as well as training and education of both staff members and patients to ensure that appropriate infection control behaviors and techniques are carried out.

## **Infection Control Practices for Hemodialysis Units**

In each chronic hemodialysis unit, policies and practices should be reviewed and updated to ensure that infection control practices recommended for hemodialysis units are implemented and rigorously followed (see Recommended Infection Control Practices for Hemodialysis Units at a Glance). Intensive efforts must be made to educate new staff members and reeducate existing staff members regarding these practices.

### ***Infection Control Precautions for All Patients***

During the process of hemodialysis, exposure to blood and potentially contaminated items can be routinely anticipated; thus, gloves are required whenever caring for a patient or touching the patient's equipment. To facilitate glove use, a supply of clean nonsterile gloves and a glove discard container should be placed near each dialysis station. Hands always should be washed after gloves are removed and between patient contacts, as well as after touching blood, body fluids, secretions, excretions, and contaminated items. A sufficient number of sinks with warm water and soap should be available to facilitate hand washing. If hands are not visibly soiled, use of a waterless antiseptic hand rub can be substituted for hand washing.

Any item taken to a patient's dialysis station could become contaminated with blood and other body fluids and serve as a vehicle of transmission to other patients either directly or by contamination of the hands of personnel. Therefore, items taken to a patient's dialysis station, including those placed on top of dialysis machines, should either be disposed of, dedicated for use only on a single patient, or cleaned and disinfected before being returned to a common clean area or used for other patients. Unused medications or supplies (e.g., syringes, alcohol swabs) taken to the patient's station should not be returned to a common clean area or used on other patients.

Additional measures to prevent contamination of clean or sterile items include a) preparing medications in a room or area separated from the patient treatment area and designated only for medications; b) not handling or storing contaminated (i.e., used) supplies, equipment, blood samples, or biohazard containers in areas where medications and clean (i.e., unused) equipment and supplies are handled; and c) delivering medications separately to each patient. Common carts should not be used within the patient treatment area to prepare or distribute medications. If trays are used to distribute medications, clean them before using for a different patient.

Intravenous medication vials labeled for single use, including erythropoetin, should not be punctured more than once (196,197). Once a needle has entered a vial labeled for single use, the sterility of the product can no longer be guaranteed. Residual medication from two or more vials should not be pooled into a single vial.

If a common supply cart is used to store clean supplies in the patient treatment area, this cart should remain in a designated area at a sufficient distance from patient stations to avoid contamination with blood. Such carts should not be moved between stations to distribute supplies.

**Infection Control Precautions for All Patients**

- Wear disposable gloves when caring for the patient or touching the patient’s equipment at the dialysis station; remove gloves and wash hands between each patient or station.
- Items taken into the dialysis station should either be disposed of, dedicated for use only on a single patient, or cleaned and disinfected before being taken to a common clean area or used on another patient.
  - Nondisposable items that cannot be cleaned and disinfected (e.g., adhesive tape, cloth-covered blood pressure cuffs) should be dedicated for use only on a single patient.
  - Unused medications (including multiple dose vials containing diluents) or supplies (e.g., syringes, alcohol swabs) taken to the patient’s station should be used only for that patient and should not be returned to a common clean area or used on other patients.
- When multiple dose medication vials are used (including vials containing diluents), prepare individual patient doses in a clean (centralized) area away from dialysis stations and deliver separately to each patient. Do not carry multiple dose medication vials from station to station.
- Do not use common medication carts to deliver medications to patients. Do not carry medication vials, syringes, alcohol swabs, or supplies in pockets. If trays are used to deliver medications to individual patients, they must be cleaned between patients.

**Schedule for Routine Testing for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Infections**

Patient Status	On Admission	Monthly	Semiannual	Annual
All patients	HBsAg,* Anti-HBc* (total), Anti-HBs,* Anti-HCV, ALT†			
HBV-susceptible, including nonresponders to vaccine		HBsAg		
Anti-HBs positive (≥10 mIU/mL), anti-HBc negative				Anti-HBs
Anti-HBs and anti-HBc positive		No additional HBV testing needed		
Anti-HCV negative		ALT	Anti-HCV	

\* Results of HBV testing should be known before the patient begins dialysis.  
 † HBsAg=hepatitis B surface antigen; Anti-HBc=antibody to hepatitis B core antigen; Anti-HBs=antibody to hepatitis B surface antigen; Anti-HCV=antibody to hepatitis C virus; ALT=alanine aminotransferase.

*(Continued on page 21)*

- Clean areas should be clearly designated for the preparation, handling, and storage of medications and unused supplies and equipment. Clean areas should be clearly separated from contaminated areas where used supplies and equipment are handled. Do not handle and store medications or clean supplies in the same or an adjacent area to where used equipment or blood samples are handled.
- Use external venous and arterial pressure transducer filters/protectors for each patient treatment to prevent blood contamination of the dialysis machines' pressure monitors. Change filters/protectors between each patient treatment, and do not reuse them. Internal transducer filters do not need to be changed routinely between patients.
- Clean and disinfect the dialysis station (e.g., chairs, beds, tables, machines) between patients.
  - Give special attention to cleaning control panels on the dialysis machines and other surfaces that are frequently touched and potentially contaminated with patients' blood.
  - Discard all fluid and clean and disinfect all surfaces and containers associated with the prime waste (including buckets attached to the machines).
- For dialyzers and blood tubing that will be reprocessed, cap dialyzer ports and clamp tubing. Place all used dialyzers and tubing in leakproof containers for transport from station to reprocessing or disposal area.

---

### **Hepatitis B Vaccination**

- Vaccinate all susceptible patients against hepatitis B.
- Test for anti-HBs 1-2 months after last dose.
  - If anti-HBs is  $<10$  mIU/mL, consider patient susceptible, revaccinate with an additional three doses, and retest for anti-HBs.
  - If anti-HBs is  $\geq 10$  mIU/mL, consider patient immune, and retest annually.
  - Give booster dose of vaccine if anti-HBs declines to  $<10$  mIU/mL and continue to retest annually.

---

### **Management of HBsAg-Positive Patients**

- Follow infection control practices for hemodialysis units for all patients.
- Dialyze HBsAg-positive patients in a separate room using separate machines, equipment, instruments, and supplies.
- Staff members caring for HBsAg-positive patients should not care for HBV-susceptible patients at the same time (e.g., during the same shift or during patient changeover).

Staff members should wear gowns, face shields, eye wear, or masks to protect themselves and prevent soiling of clothing when performing procedures during which spurt-ing or spattering of blood might occur (e.g., during initiation and termination of dialysis, cleaning of dialyzers, and centrifugation of blood). Such protective clothing or gear should be changed if it becomes soiled with blood, body fluids, secretions, or excre-tions. Staff members should not eat, drink, or smoke in the dialysis treatment area or in the laboratory. However, patients can be served meals or eat food brought from home at their dialysis station. The glasses, dishes, and other utensils should be cleaned in the usual manner; no special care of these items is needed.

**Cleaning and Disinfection.** Establish written protocols for cleaning and disinfecting surfaces and equipment in the dialysis unit, including careful mechanical cleaning be-fore any disinfection process (Table 2). If the manufacturer has provided instructions on sterilization or disinfection of the item, these instructions should be followed. For each chemical sterilant and disinfectant, follow the manufacturer's instructions regarding use, including appropriate dilution and contact time.

After each patient treatment, clean environmental surfaces at the dialysis station, including the dialysis bed or chair, countertops, and external surfaces of the dialysis machine, including containers associated with the prime waste. Use any soap, deter-gent, or detergent germicide. Between uses of medical equipment (e.g., scissors, he-mostats, clamps, stethoscopes, blood pressure cuffs), clean and apply a hospital disinfectant (i.e., low-level disinfection); if the item is visibly contaminated with blood, use a tuberculocidal disinfectant (i.e., intermediate-level disinfection).

For a blood spill, immediately clean the area with a cloth soaked with a tubercu-locidal disinfectant or a 1:100 dilution of household bleach (300–600 mg/L free chlorine) (i.e., intermediate-level disinfection). The staff member doing the cleaning should wear gloves, and the cloth should be placed in a bucket or other leakproof container. After all visible blood is cleaned, use a new cloth or towel to apply disinfectant a second time.

Published methods should be used to clean and disinfect the water treatment and distribution system and the internal circuits of the dialysis machine, as well as to repro-

**TABLE 2. Disinfection procedures recommended for commonly used items or surfaces in hemodialysis units**

<b>Item or Surface</b>	<b>Low-Level Disinfection*</b>	<b>Intermediate-Level Disinfection*</b>
Gross blood spills or items contaminated with visible blood		X
Hemodialyzer port caps		X
Interior pathways of dialysis machine		X
Water treatment and distribution system	X	X <sup>†</sup>
Scissors, hemostats, clamps, blood pressure cuffs, stethoscopes	X	X <sup>§</sup>
Environmental surfaces, including exterior surfaces of hemodialysis machines	X	

\* Careful mechanical cleaning to remove debris should always be done before disinfection.

<sup>†</sup> Water treatment and distribution systems of dialysis fluid concentrates require more extensive disinfection if significant biofilm is present within the system.

<sup>§</sup> If item is visibly contaminated with blood, use a tuberculocidal disinfectant.

cess dialyzers for reuse (see Suggested Readings). These methods are designed to control bacterial contamination, but will also eliminate bloodborne viruses. For single-pass machines, perform rinsing and disinfection procedures at the beginning or end of the day. For batch recirculating machines, drain, rinse, and disinfect after each use. Follow the same methods for cleaning and disinfection if a blood leak has occurred, regardless of the type of dialysis machine used. Routine bacteriologic assays of water and dialysis fluids should be performed according to the recommendations of the Association for the Advancement of Medical Instrumentation (see Suggested Readings).

Venous pressure transducer protectors should be used to cover pressure monitors and should be changed between patients, not reused. If the external transducer protector becomes wet, replace immediately and inspect the protector. If fluid is visible on the side of the transducer protector that faces the machine, have qualified personnel open the machine after the treatment is completed and check for contamination. This includes inspection for possible blood contamination of the internal pressure tubing set and pressure sensing port. If contamination has occurred, the machine must be taken out of service and disinfected using either 1:100 dilution of bleach (300–600 mg/L free chlorine) or a commercially available, EPA-registered tuberculocidal germicide before reuse. Frequent blood line pressure alarms or frequent adjusting of blood drip chamber levels can be an indicator of this problem. Taken separately, these incidents could be characterized as isolated malfunctions. However, the potential public health significance of the total number of incidents nationwide make it imperative that all incidents of equipment contamination be reported immediately to the FDA (800-FDA-1088).

Housekeeping staff members in the dialysis facility should promptly remove soil and potentially infectious waste and maintain an environment that enhances patient care. All disposable items should be placed in bags thick enough to prevent leakage. Wastes generated by the hemodialysis facility might be contaminated with blood and should be considered infectious and handled accordingly. These solid medical wastes should be disposed of properly in an incinerator or sanitary landfill, according to local and state regulations governing medical waste disposal.

***Hemodialysis in Acute-Care Settings.*** For patients with acute renal failure who receive hemodialysis in acute-care settings, Standard Precautions as applied in all health-care settings are sufficient to prevent transmission of bloodborne viruses. However, when chronic hemodialysis patients receive maintenance hemodialysis while hospitalized, infection control precautions specifically designed for chronic hemodialysis units (see Recommended Practices at a Glance) should be applied to these patients. If both acute and chronic renal failure patients receive hemodialysis in the same unit, these infection control precautions should be applied to all patients.

Regardless of where in the acute-care setting chronic hemodialysis patients receive dialysis, the HBsAg status of all such patients should be ascertained at the time of admission to the hospital, by either a written report from the referring center (including the most recent date testing was performed) or by a serologic test. The HBV serologic status should be prominently placed in patients' hospital records, and all health-care personnel assigned to these patients, as well as the infection control practitioner, should be aware of the patients' serologic status. While hospitalized, HBsAg-positive chronic hemodialysis patients should undergo dialysis in a separate room and use separate machines, equipment, instruments, supplies, and medications designated only for HBsAg-positive patients (see Prevention and Management of HBV Infection). While HBsAg-positive patients are receiving dialysis, staff members who are caring for them should not care for susceptible patients.


### Routine Serologic Testing

**Chronic Hemodialysis Patients.** Routinely test all chronic hemodialysis patients for HBV and HCV infection (see Recommended Practices at a Glance), promptly review results, and ensure that patients are managed appropriately based on their testing results (see later recommendations for each virus). Communicate test results (positive and negative) to other units or hospitals when patients are transferred for care. Routine testing for HDV or HIV infection for purposes of infection control is not recommended.

The HBV serologic status (i.e., HBsAg, total anti-HBc, and anti-HBs) of all patients should be known before admission to the hemodialysis unit. For patients transferred from another unit, test results should be obtained before the patients' transfer. If a patient's HBV serologic status is not known at the time of admission, testing should be completed within 7 days. The hemodialysis unit should ensure that the laboratory performing the testing for anti-HBs can define a 10 mIU/mL concentration to determine protective levels of antibody.

Routine HCV testing should include use of both an EIA to test for anti-HCV and supplemental or confirmatory testing with an additional, more specific assay (Figure). Use of RT-PCR for HCV RNA as the primary test for routine screening is not recommended because few HCV infections will be identified in anti-HCV negative patients.

**FIGURE. Algorithm for hepatitis C virus (HCV) infection testing among persons who are asymptomatic**



**Source:** CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No. RR-19):27.



However, if ALT levels are persistently abnormal in patients who are anti-HCV negative in the absence of another etiology, testing for HCV RNA should be considered (for proper specimen collection and handling, see Hepatitis C Virus Infection, Screening and Diagnostic Tests).

**Hemodialysis Staff Members.** Previously, testing for HBV infection was recommended for all staff members at the time of employment and for susceptible staff members at routine intervals thereafter (198); however, such testing is no longer considered necessary. The risk for HBV infection among hemodialysis staff members is no greater than that for other health-care workers. Thus, routine testing of staff members is not recommended except when required to document response to hepatitis B vaccination (see Postvaccination Testing and Revaccination of Nonresponders). Routine testing of staff members for HCV, HDV, or HIV infection is not recommended.

### Hepatitis B Vaccination

**Vaccine Schedule and Dose.** Hepatitis B vaccination is recommended for all susceptible chronic hemodialysis patients and for all staff members (Table 3). Vaccination is recommended for pre-end-stage renal disease patients before they become dialysis dependent and for peritoneal and home dialysis patients because they might require in-center hemodialysis. Hepatitis B vaccine should be administered by the intramuscular route and only in the deltoid muscle for adults and children. Intradermal or subcutaneous administration of hepatitis B vaccine is not recommended.

If an adult patient begins the vaccine series with a standard dose before beginning hemodialysis treatment, then moves to hemodialysis treatment before completing the series, complete the series using the higher dose recommended for hemodialysis patients (Table 3). No specific recommendations have been made for higher doses for pediatric hemodialysis patients. If a lower than recommended vaccine dose is administered to either adults or children, the dose should be repeated.

**TABLE 3. Doses and schedules of licensed hepatitis B vaccines for hemodialysis patients and staff members**

Group	Recombivax HB™*			Engerix-B®†		
	Dose	Volume	Schedule	Dose	Volume	Schedule
Patients aged ≥20 years						
Predialysis‡	10 µg	1.0 mL	0, 1, and 6 months	20 µg	1.0 mL	0, 1, and 6 months
Dialysis-dependent	40 µg	1.0 mL†	0, 1, and 6 months	40 µg	2–1.0 mL doses at one site	0, 1, 2, and 6 months
Patients aged <20 years**	5 µg	0.5 mL	0, 1, and 6 months	10 µg	0.5 mL	0, 1, and 6 months
Staff members aged ≥20 years	10 µg	1.0 mL	0, 1, and 6 months	20 µg	1.0 mL	0, 1, and 6 months

\* Merck & Company, Inc., West Point, Pennsylvania.

† SmithKline Beecham Biologicals, Philadelphia, Pennsylvania.

‡ Immunogenicity might depend on degree of renal insufficiency.

† Special formulation.

\*\* Doses for all persons aged <20 years approved by the U.S. Food and Drug Administration; for hemodialysis patients, higher doses might be more immunogenic.

**Note:** All doses should be administered in the deltoid by the intramuscular route.

If the vaccination series is interrupted after the first dose, the second dose should be administered as soon as possible. For the three-dose primary vaccine series, the second and third doses should be separated by an interval of at least 2 months; if only the third dose is delayed, that dose should be administered when convenient. When hepatitis B vaccine has been administered at the same time as other vaccines, no interference with the antibody response of the other vaccines has been demonstrated.

**Postvaccination Testing and Revaccination of Nonresponders.** Test all vaccinees for anti-HBs 1–2 months after the last primary vaccine dose, to determine their response to the vaccine (adequate response is defined as  $\geq 10$  mIU/mL). Patients and staff members who do not respond to the primary vaccine series should be revaccinated with three additional doses and retested for response. No additional doses of vaccine are warranted for those who do not respond to the second series.

Evaluate staff members who do not respond to revaccination to determine if they are HBsAg positive (199). Persons who are HBsAg positive should be counseled accordingly (e.g., need for medical evaluation, vaccination of sexual and household contacts). Primary nonresponders to vaccination who are HBsAg negative should be considered susceptible to HBV infection and counseled regarding precautions to prevent HBV infection and the need to obtain postexposure prophylaxis with hepatitis B immune globulin for any known or probable percutaneous or mucosal exposure to HBsAg-positive blood (199).

**Follow-Up of Vaccine Responders.** Retest patients who respond to the vaccine annually for anti-HBs. If anti-HBs declines to  $< 10$  mIU/mL, administer a booster dose of hepatitis B vaccine and continue to retest annually. Retesting immediately after the booster dose is not necessary. For staff members who respond to the vaccine, booster doses of vaccine are not necessary, and periodic serologic testing to monitor antibody concentrations is not recommended (199).

**Patients with a History of Vaccination.** Routine childhood vaccination against hepatitis B has been recommended since 1991 and routine adolescent vaccination since 1995 (89,198). Thus, many persons who develop end-stage renal failure will have a history of vaccination against hepatitis B. These persons should have responded to the vaccine when their immune status was normal, but if their anti-HBs levels are  $< 10$  mIU/mL when they begin dialysis, they should be revaccinated with a complete primary series.

### **Prevention and Management of HBV Infection**

Preventing HBV transmission among chronic hemodialysis patients requires a) infection control precautions recommended for all hemodialysis patients; b) routine serologic testing for markers of HBV infection and prompt review of results; c) isolation of HBsAg-positive patients with dedicated room, machine, other equipment, supplies, and staff members; and d) vaccination. Additional infection control practices are needed because of the potential for environmentally mediated transmission of HBV, rather than internal contamination of dialysis machines. The need for routine follow-up testing, vaccination, or isolation is based on patients' serologic status (Table 1 and Recommended Practices at a Glance).

**HBV-Susceptible Patients.** Vaccinate all susceptible patients (see Hepatitis B Vaccination). Test susceptible patients monthly for HBsAg, including those who a) have not yet received hepatitis B vaccine, b) are in the process of being vaccinated, or c) have not adequately responded to vaccination. Although the incidence of HBV infection is low

among chronic hemodialysis patients, preventing transmission depends on timely detection of patients converting from HBsAg negative to HBsAg positive and rapid implementation of isolation procedures before cross-contamination can occur.

**HBsAg Seroconversions.** Report HBsAg-positive seroconversions to the local health department as required by law or regulation. When a seroconversion occurs, review all patients' routine laboratory test results to identify additional cases. Perform additional testing as indicated later in this section. Investigate potential sources for infection to determine if transmission might have occurred within the dialysis unit, including review of newly infected patients' recent medical history (e.g., blood transfusion, hospitalization), history of high-risk behavior (e.g., injecting-drug use, sexual activity), and unit practices and procedures.

In patients newly infected with HBV, HBsAg often is the only serologic marker initially detected; repeat HBsAg testing and test for anti-HBc (including IgM anti-HBc) 1–2 months later. Six months later, repeat HBsAg testing and test for anti-HBs to determine clinical outcome and need for counseling, medical evaluation, and vaccination of contacts. Patients who become HBsAg negative are no longer infectious and can be removed from isolation.

**HBV-Infected Patients.** To isolate HBsAg-positive patients, designate a separate room for their treatment and dedicate machines, equipment, instruments, supplies, and medications that will not be used by HBV-susceptible patients. Most importantly, staff members who are caring for HBsAg-positive patients should not care for susceptible patients at the same time, including during the period when dialysis is terminated on one patient and initiated on another.

Newly opened units should have isolation rooms for the dialysis of HBsAg-positive patients. For existing units in which a separate room is not possible, HBsAg-positive patients should be separated from HBV-susceptible patients in an area removed from the mainstream of activity and should undergo dialysis on dedicated machines. If a machine that has been used on an HBsAg-positive patient is needed for an HBV-susceptible patient, internal pathways of the machine can be disinfected using conventional protocols and external surfaces cleaned using soap and water or a detergent germicide.

Dialyzers should not be reused on HBsAg-positive patients. Because HBV is efficiently transmitted through occupational exposure to blood, reprocessing dialyzers from HBsAg-positive patients might place HBV-susceptible staff members at increased risk for infection.

Chronically infected patients (i.e., those who are HBsAg positive, total anti-HBc positive, and IgM anti-HBc negative) are infectious to others and are at risk for chronic liver disease. They should be counseled regarding preventing transmission to others, their household and sexual partners should receive hepatitis B vaccine, and they should be evaluated (by consultation or referral, if appropriate) for the presence or development of chronic liver disease according to current medical practice guidelines. Persons with chronic liver disease should be vaccinated against hepatitis A, if susceptible.

Chronically infected patients do not require any routine follow-up testing for purposes of infection control. However, annual testing for HBsAg is reasonable to detect the small percentage of HBV-infected patients who might lose their HBsAg.

**HBV-Immune Patients.** Annual anti-HBs testing of patients who are positive for anti-HBs ( $\geq 10$  mIU/mL) and negative for anti-HBc determines the need for booster doses of

vaccine to ensure that protective levels of antibody are maintained. No routine follow-up testing is necessary for patients who are positive for both anti-HBs and anti-HBc.

HBV-immune patients can undergo dialysis in the same area as HBsAg-positive patients, or they can serve as a geographic buffer between HBsAg-positive and HBV-susceptible patients. Staff members can be assigned to care for both infected and immune patients on the same shift.

**Isolated Anti-HBc-Positive Patients.** Patients who test positive for isolated anti-HBc (i.e., those who are anti-HBc positive, HBsAg negative, and anti-HBs negative) should be retested on a separate serum sample for total anti-HBc, and if positive, for IgM anti-HBc. The following guidelines should be used for interpretation and follow-up:

- If total anti-HBc is negative, consider patient susceptible, and follow recommendations for vaccination.
- If total anti-HBc is positive and IgM anti-HBc is negative, follow recommendations for vaccination.
  - If anti-HBs is <10 mIU/mL even after revaccination, test for HBV DNA.
  - If HBV DNA is negative, consider patient susceptible (i.e., the anti-HBc result is a false positive), and test monthly for HBsAg.
  - If HBV DNA is positive, consider patient as having past infection or “low-level” chronic infection (i.e., the anti-HBc result is a true positive); no further testing is necessary.
    - Isolation is not necessary because HBsAg is not detectable.
- If both total and IgM anti-HBc are positive, consider patient recently infected and test for anti-HBs in 4–6 months; no further routine testing is necessary.
  - Isolation is not necessary because HBsAg is not detectable.

### ***Prevention and Management of HCV Infection***

HCV transmission within the dialysis environment can be prevented by strict adherence to infection control precautions recommended for all hemodialysis patients (see Recommended Practices at a Glance). Although isolation of HCV-infected patients is not recommended, routine testing for ALT and anti-HCV is important for monitoring transmission within centers and ensuring that appropriate precautions are being properly and consistently used.

**HCV-Negative Patients.** Monthly ALT testing will facilitate timely detection of new infections and provide a pattern from which to determine when exposure or infection might have occurred. In the absence of unexplained ALT elevations, testing for anti-HCV every 6 months should be sufficient to monitor the occurrence of new HCV infections. If unexplained ALT elevations are observed in patients who are anti-HCV negative, repeat anti-HCV testing is warranted. If unexplained ALT elevations persist in patients who repeatedly test anti-HCV negative, testing for HCV RNA should be considered.

**Anti-HCV Seroconversions.** Report anti-HCV-positive seroconversions to the local health department as required by law or regulation. When a seroconversion occurs, review all other patients' routine laboratory test results to identify additional cases. Perform additional testing as indicated later in this section. Investigate potential sources

for infection to determine if transmission might have occurred within the dialysis unit, including review of newly infected patients' recent medical history (e.g., blood transfusion, hospitalization), history of high-risk behavior (e.g., injecting-drug use, sexual activity), and unit practices and procedures.

If  $\geq 1$  patient seroconverts from anti-HCV negative to positive during a 6-month period, more frequent (e.g., every 1–3 months) anti-HCV testing of HCV-negative patients could be warranted for a limited time (e.g., 3–6 months) to detect additional infections. If no additional newly infected patients are identified, resume semiannual testing. If ongoing HCV transmission among patients is identified, implement control measures based on results of investigation of potential sources for transmission and monitor their effectiveness (e.g., perform more frequent anti-HCV testing of HCV-negative patients for 6–12 months before resuming semiannual testing).

**HCV-Positive Patients.** Patients who are anti-HCV positive (or HCV RNA positive) do not have to be isolated from other patients or dialyzed separately on dedicated machines. Furthermore, they can participate in dialyzer reuse programs. Unlike HBV, HCV is not transmitted efficiently through occupational exposures. Thus, reprocessing dialyzers from HCV-positive patients should not place staff members at increased risk for infection.

HCV-positive persons should be evaluated (by consultation or referral, if appropriate) for the presence or development of chronic liver disease according to current medical practice guidelines. They also should receive information concerning how they can prevent further harm to their liver and prevent transmitting HCV to others (116,141). Persons with chronic liver disease should be vaccinated against hepatitis A, if susceptible.

### ***Prevention and Management of HDV Infection***

Because of the low prevalence of HDV infection in the United States, routine testing of hemodialysis patients is not necessary or recommended. However, if a patient is known to be infected with HDV, or if evidence exists of transmission of HDV in a dialysis center, screening for delta antibody is warranted. Because HDV depends on an HBV-infected host for replication, prevention of HBV infection will prevent HDV infection in a person susceptible to HBV. Patients who are known to be infected with HDV should be isolated from all other dialysis patients, especially those who are HBsAg-positive.

### ***Prevention and Management of HIV Infection***

Routine testing of hemodialysis patients for HIV infection for infection control purposes is not necessary or recommended. However, patients with risk factors for HIV infection should be tested so that, if infected, they can receive proper medical care and counseling regarding preventing transmission of the virus (201).

Infection control precautions recommended for all hemodialysis patients (see Recommended Practices at a Glance) are sufficient to prevent HIV transmission between patients. HIV-infected patients do not have to be isolated from other patients or dialyzed separately on dedicated machines. In addition, they can participate in dialyzer reuse programs. Because HIV is not transmitted efficiently through occupational exposures, reprocessing dialyzers from HIV-positive patients should not place staff members at increased risk for infection.

### ***Prevention and Management of Bacterial Infections***

Follow published guidelines for judicious use of antimicrobials, particularly vancomycin, to reduce selection for antimicrobial-resistant pathogens (202). Infection control precautions recommended for all hemodialysis patients (see Recommended Practices at a Glance) are adequate to prevent transmission for most patients infected or colonized with pathogenic bacteria, including antimicrobial-resistant strains. However, additional infection control precautions should be considered for treatment of patients who might be at increased risk for transmitting pathogenic bacteria. Such patients include those with either a) an infected skin wound with drainage that is not contained by dressings (the drainage does not have to be culture positive for VRE, MRSA, or any specific pathogen) or b) fecal incontinence or diarrhea uncontrolled with personal hygiene measures. For these patients, consider using the following additional precautions: a) staff members treating the patient should wear a separate gown over their usual clothing and remove the gown when finished caring for the patient and b) dialyze the patient at a station with as few adjacent stations as possible (e.g., at the end or corner of the unit).

## **SURVEILLANCE FOR INFECTIONS AND OTHER ADVERSE EVENTS**

Develop and maintain a separate centralized record-keeping system (e.g., log book or electronic file) to record the results of patients' vaccination status, serologic testing results for viral hepatitis (including ALT), episodes of bacteremia or loss of the vascular access caused by infection (including date of onset, site of infection, genus and species of the infecting organism, and selected antimicrobial susceptibility results),\* and adverse events (e.g., blood leaks and spills, dialysis machine malfunctions). Designate a staff person to promptly review the results of routine testing each time such testing is performed and periodically review recorded episodes of bacteremia or vascular access infections. Specify a procedure for actions required when changes occur in test results or in the frequency of episodes of bacteremias or vascular access loss because of infection. Maintain records for each patient that include the location of the dialysis station and machine number used for each dialysis session and the names of staff members who connect and disconnect the patient to and from a machine.

## **INFECTION CONTROL TRAINING AND EDUCATION**

Training and education is recommended for both staff members and patients (or their family care givers). Training should be appropriate to the cognitive level of the staff member, patient, or family member, and rationales should be provided for appropriate infection control behaviors and techniques to increase compliance. Regulations and recommendations regarding infection control training for health-care workers in general, and dialysis personnel in particular, have been previously published

---

\*Hemodialysis units interested in participating in a formal surveillance system for bacterial infections should consult CDC's Surveillance for Bloodstream and Vascular Access Infections in Outpatient Hemodialysis Centers. More information is available on the Internet at <[http://www.cdc.gov/ncidod/hip/Dialysis/DSN\\_manual.PDF](http://www.cdc.gov/ncidod/hip/Dialysis/DSN_manual.PDF)>.

(180,203–205). The following recommendations are intended to highlight and augment the earlier recommendations.

- Training and education for all employees at risk for occupational exposure to blood should be provided at least annually, given to new employees before they begin working in the unit, and documented. At a minimum, they should include information on the following topics:
  - proper hand hygiene technique;
  - proper use of protective equipment;
  - modes of transmission for bloodborne viruses, pathogenic bacteria, and other microorganisms as appropriate;
  - infection control practices recommended for hemodialysis units and how they differ from Standard Precautions recommended for other health-care settings;
  - proper handling and delivery of patient medications;
  - rationale for segregating HBsAg-positive patients with a separate room, machine, instruments, supplies, medications, and staff members;
  - proper infection control techniques for initiation, care, and maintenance of access sites;
  - housekeeping to minimize transmission of microorganisms, including proper methods to clean and disinfect equipment and environmental surfaces; and
  - centralized record keeping to monitor and prevent complications, including routine serologic testing results for HBV and HCV, hepatitis B vaccine status, episodes of bacteremia and loss of access caused by infection, and other adverse events. Records of surveillance for water and dialysate quality should also be maintained.
- Training and education of patients (or family members for patients unable to be responsible for their own care) regarding infection control practices should be given on admission to dialysis and at least annually thereafter and should address the following topics:
  - personal hygiene and hand washing technique;
  - patient responsibility for proper care of the access and recognition of signs of infection, which should be reviewed each time the patient has a change in access type; and
  - recommended vaccinations (206).

## FUTURE DIRECTIONS

Infection control strategies that prevent and control HBV infection among hemodialysis patients are well-established. Areas that need additional research include determining the ideal hepatitis B vaccine dosage regimen for pre- and postdialysis pediatric patients and for predialysis adult patients, as well as the optimal timing for follow-up

testing and administration of booster doses among vaccine responders. In addition, further studies are needed to clarify the specific factors responsible for transmission of HCV among hemodialysis patients and to evaluate the effect of the current recommendations on prevention and control of HCV infection in this setting.

Many areas related to bacterial infections in chronic hemodialysis patients need additional information. Studies are needed on the prevalence and epidemiology of bacterial infections among chronic hemodialysis patients and the patient care practices (e.g., those related to vascular access care and puncture) that would be most useful in preventing bacterial infections. Because of the prominent role of dialysis patients in the epidemic of antimicrobial resistance, researchers need to learn more regarding optimal strategies to ensure judicious use of antimicrobials in these patients. Additional topics for future research include determining the frequency of transmission of pathogenic bacteria in the dialysis unit and whether additional precautions are necessary to prevent such transmission.

This document is available on the Internet at <<http://www.cdc.gov/hepatitis>>. Copies also can be obtained by using the order form at this Internet site or by writing the Hepatitis Branch, Mailstop G37, CDC, Atlanta, GA 30333.

#### References

1. National Institutes of Health. 1999 annual data report. US Renal Data System. Bethesda, MD: US Department of Health and Human Services, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, April 1999.
2. Hörl WH. Neutrophil function and infections in uremia. *Am J Kidney Dis* 1999;33:xliv-ii.
3. Snyderman DR, Bryan JA, Hanson B. Hemodialysis-associated hepatitis in the United States—1972. *J Infect Dis* 1975;132:109–13.
4. Snyderman DR, Bregman D, Bryan J. Hemodialysis-associated hepatitis in the United States, 1974. *J Infect Dis* 1977;135:687–91.
5. Alter MJ, Favero MS, Petersen NJ, Doto IL, Leger RT, Maynard JE. National surveillance of dialysis-associated hepatitis and other diseases: 1976 and 1980. *Dialysis & Transplantation* 1983;12:860–5.
6. Alter MJ, Favero MS, Maynard JE. Hepatitis B vaccine use in chronic hemodialysis centers in the United States. *JAMA* 1985;254:3200–2.
7. Alter MJ, Favero MS, Maynard JE. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. *J Infect Dis* 1986;153:1149–51.
8. Alter MJ, Favero MS, Miller JK, Moyer LA, Bland LA. National surveillance of dialysis-associated diseases in the United States, 1987. *ASAIO Transactions* 1989;35:820–31.
9. Alter MJ, Favero MS, Miller JK, Moyer LA, Bland LA. National surveillance of dialysis-associated diseases in the United States, 1988. *ASAIO Transactions* 1990;36:107–18.
10. Alter MJ, Favero MS, Miller JK, Moyer LA, Bland LA. National surveillance of dialysis-associated diseases in the United States, 1989. *ASAIO Transactions* 1991;37:97–109.
11. Tokars JI, Alter MJ, Favero MS, Moyer LA, Bland LA. National surveillance of hemodialysis associated diseases in the United States, 1990. *ASAIO J* 1993;39:71–80.
12. Tokars JI, Alter MJ, Favero MS, Moyer LA, Bland LA. National surveillance of dialysis associated diseases in the United States, 1991. *ASAIO J* 1993;39:966–75.
13. Tokars JI, Alter MJ, Favero MS, Moyer LA, Miller E, Bland LA. National surveillance of dialysis associated diseases in the United States, 1992. *ASAIO J* 1994;40:1020–31.
14. Tokars JI, Alter MJ, Favero MS, Moyer LA, Miller E, Bland LA. National surveillance of dialysis associated diseases in the United States, 1993. *ASAIO J* 1996;42:219–29.
15. Tokars JI, Alter MJ, Miller E, Moyer LA, Favero MS. National surveillance of dialysis associated diseases in the United States—1994. *ASAIO J* 1997;43:108–19.



16. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis associated diseases in the United States, 1995. *ASAIO J* 1998;44:98–107.
17. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 1996. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, 1998:1–59.
18. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 1997. *Semin Dial* 2000;13:75–85.
19. CDC. Hepatitis: control measures for hepatitis B in dialysis centers. Atlanta, GA: US Department of Health, Education, and Welfare, Public Health Services, CDC, 1977. HEW publication no. (CDC) 78-8358 (Viral Hepatitis Investigations and Control Series).
20. CDC. Recommendations of the Immunization Practices Advisory Committee (ACIP): inactivated hepatitis B virus vaccine. *MMWR* 1982;31:317–22, 327–8.
21. CDC. Outbreaks of hepatitis B virus infection among hemodialysis patients—California, Nebraska, and Texas, 1994. *MMWR* 1996;45:285–9.
22. Favero MS, Alter MJ. The reemergence of hepatitis B virus infection in hemodialysis centers. *Semin Dial* 1996;9:373–4.
23. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. *Clin Chest Med* 1999;20:303–16.
24. Favero MS, Tokars JI, Arduino MJ, Alter MJ. Nosocomial infections associated with hemodialysis. In: Mayhall CG, ed. *Hospital epidemiology and infection control*, 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 1999, 897–917.
25. Tokars JI. Description of a new surveillance system for bloodstream and vascular access infections in outpatient hemodialysis centers. *Semin Dial* 2000;13:97–100.
26. Alter HJ, Seeff LB, Kaplan PM, et al. Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. *N Engl J Med* 1976;295:909–13.
27. Shikata T, Karasawa T, Abe K, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. *J Infect Dis* 1977;136:571–6.
28. Favero MS, Bond WW, Petersen NJ, Berquist KR, Maynard JE. Detection methods for study of the stability of hepatitis B antigen on surfaces. *J Infect Dis* 1974;129:210–2.
29. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. *Lancet* 1981;1:550–1.
30. Favero MS, Maynard JE, Petersen NJ, et al. Hepatitis-B antigen on environmental surfaces [Letter]. *Lancet* 1973;2:1455.
31. Snyderman DR, Bryan JA, Macon EJ, Gregg MB. Hemodialysis-associated hepatitis: report of an epidemic with further evidence on mechanisms of transmission. *Am J Epidemiol* 1976;104:563–70.
32. Kantor RJ, Hadler SC, Schreeder MT, et al. Outbreak of hepatitis B in a dialysis unit, complicated by false positive HBsAg test results. *Dialysis & Transplantation* 1979;8:232–5.
33. Carl M, Francis DP, Maynard JE. A common-source outbreak of hepatitis B in a hemodialysis unit. *Dialysis & Transplantation* 1983;12:222–9.
34. Alter MJ, Ahtone J, Maynard JE. Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit. *Ann Intern Med* 1983;99:330–3.
35. Niu MT, Penberthy LT, Alter MJ, Armstrong CW, Miller GB, Hadler SC. Hemodialysis-associated hepatitis B: report of an outbreak. *Dialysis & Transplantation* 1989;18:542–6, 555.
36. Anonymous. Decrease in the incidence of hepatitis in dialysis units associated with prevention programme: Public Health Laboratory Service Survey. *BMJ* 1974;4:751–4.
37. Anonymous. Hepatitis B in retreat from dialysis units in United Kingdom in 1973: Public Health Laboratory Service Survey. *Br Med J* 1976;1:1579–81.
38. Najem GR, Louria DB, Thind IS, et al. Control of hepatitis B infection: the role of surveillance and an isolation hemodialysis center. *JAMA* 1981;245:153–7.

39. Hutin YJF, Goldstein ST, Varma JK, et al. An outbreak of hospital-acquired hepatitis B virus infection among patients receiving hemodialysis. *Infect Control Hosp Epidemiol* 1999;20:731–5.
40. McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. *J Infect Dis* 1985;151:599–603.
41. Dienstag JL. Immunopathogenesis of the extrahepatic manifestations of hepatitis B virus infections. *Springer Semin Immunopathol* 1981;3:461–72.
42. Hoofnagle JH, Di Bisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. *Semin Liver Dis* 1991;11:73–83.
43. Beasley RP, Hwang L-Y, Lin C-C, Chin C-S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. *Lancet* 1981;2:1129–33.
44. Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the “healthy” HBsAg carrier state. *Hepatology* 1987;7:758–63.
45. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen—positive Alaska Native carriers. *Arch Intern Med* 1990;150:1051–4.
46. Ortiz-Interian CJ, de Medina MD, Perez GO, et al. Recurrence and clearance of hepatitis B surface antigenemia in a dialysis patient infected with the human immunodeficiency virus. *Am J Kidney Dis* 1990;xvi:154–6.
47. Davis CL, Gretch DR, Carithers RL. Hepatitis B and transplantation. *Infect Dis Clin North Am* 1995;9:925–41.
48. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. *N Engl J Med* 1997;336:347–56.
49. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med* 1999;341:1256–63.
50. Kloster B, Kramer R, Eastlund T, Grossman B, Zarva B. Hepatitis B surface antigenemia in blood donors following vaccination. *Transfusion* 1995;35:475–7.
51. Lunn ER, Hoggarth BJ, Cook WJ. Prolonged hepatitis B surface antigenemia after vaccination. *Pediatrics* 2000;105:E81.
52. Hadler SC, Murphy B, Schable CA, Heyward WL, Francis DP, Kane MA. Epidemiological analysis of the significance of low-positive test results for antibody to hepatitis B surface and core antigens. *J Clin Microbiol* 1984;19:521–5.
53. Levine OS, Vlahov D, Koehler J, Cohn W, Spronk AM, Nelson KE. Seroepidemiology of hepatitis B virus in a population of injecting drug users: association with drug injection patterns. *Am J Epidemiol* 1995;142:331–41.
54. Silva AE, McMahon BJ, Parkinson AJ, Sjogren MH, Hoofnagle JH, Di Bisceglie AM. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. *Clin Infect Dis* 1998;26:895–7.
55. McMahon BJ, Parkinson AJ, Helminiak C, et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. *Gastroenterology* 1992;103:590–4.
56. Lai C-L, Lau JYN, Yeoh E-K, Chang W-K, Lin H-S. Significance of isolated anti-HBc seropositivity by ELISA: implications and the role of radioimmunoassay. *J Med Virol* 1992;36:180–3.
57. Lai C-L, Chien R-N, Leung NWY, et al, and the Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. *N Engl J Med* 1998;339:61–8.
58. Hadler SC, Margolis HS. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. In: Remington JS, Swartz MN, eds. *Current clinical topics in infectious diseases*. Boston, MA: Blackwell Scientific Publications, 1992:282–308.
59. Averbhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. *Am J Prev Med* 1998;15:1–8.

60. Maupas P, Goudeau A, Coursaget P, et al. Vaccine against hepatitis B—18 months prevention in a high risk setting. *Med Microbiol Immunol (Berl)* 1978;166:109–18.
61. Grob P. Hepatitis B vaccination of renal transplant and hemodialysis patients. *Scand J Infect Dis* 1983;38:28–32.
62. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmunness W, and the Dialysis Vaccine Trial Study Group. Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. *N Engl J Med* 1984;311:496–501.
63. de Graeff PA, Dankert J, de Zeeuw D, Gips CH, van der Hem GK. Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. *Nephron* 1985;40:155–60.
64. Carletti P, Bibiano L, Boggi R, et al. HBV infection in hemodialysis patients: monitoring and prevention. *Nephron* 1992;61:269–70.
65. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuño J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. *Am J Nephrol* 1996;16:95–7.
66. van Geelen JA, Schalm SW, de Visser EM, Heijtkink RA. Immune response to hepatitis B vaccine in hemodialysis patients. *Nephron* 1987;45:216–8.
67. Bruguera M, Cremades M, Mayor A, Sánchez Tapias JM, Rodés J. Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients. *Postgrad Med J* 1987;63(Supp 2):155–8.
68. Bruguera M, Rodicio JL, Alcazar JM, Oliver A, Del Rio G, Esteban-Mur R. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. *Vaccine* 1990;8(Suppl):S47–S49.
69. Waite NM, Thomson LG, Goldstein MB. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. *J Am Soc Nephrol* 1995;5:1930–4.
70. Chang PC, Schrandt-van der Meer AM, van Dorp WT, van Leer E. Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. *Nephrol Dial Transplant* 1996;11:191–3.
71. Swan AM, DeVita MV. Higher response rate to hepatitis B vaccination observed in chronic hemodialysis patients [Letter]. *Clin Nephrol* 1997;47:207–8.
72. Radovic MM, Ostric V, Djukanovic LJ. Complete seroconversion after vaccination against hepatitis B virus in hemodialysis patients [Letter]. *Clin Nephrol* 1997;47:206.
73. Navarro JF, Teruel JL, Mateos M, Ortuño J. Hepatitis C virus infection decreases the effective antibody response to hepatitis B vaccine in hemodialysis patients. *Clin Nephrol* 1994;41:113–6.
74. Kamel M, El Manialawi M, Miller DF. Recombinant hepatitis B vaccine immunogenicity in presence of hepatitis C virus seropositivity [Letter]. *Lancet* 1994;343:552.
75. Cheng C-H, Huang C-C, Leu M-L, Chiang C-YF, Wu M-S, Lai P-C. Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection. *Vaccine* 1997;15:1353–7.
76. Fraser GM, Ochana N, Fenyves D, et al. Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. *J Hepatol* 1994;21:450–4.
77. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccine in patients with chronic renal failure before dialysis. *J Infect Dis* 1988;157:332–7.
78. Dukes CS, Street AC, Starling JF, Hamilton JD. Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis. *Vaccine* 1993;11:1229–32.
79. Callis LM, Clanxet J, Fortuny G, Caballeria J, Carrasco JL, Lardinois R. Hepatitis B virus infection and vaccination in children undergoing hemodialysis. *Acta Paediatr* 1985;74:213–8.
80. Drachman R, Isacson M, Rudensky B, Drukker A. Vaccination against hepatitis B in children and adolescent patients on dialysis. *Nephrol Dial Transplant* 1989;4:372–4.
81. Watkins SL, Hogg RJ, Alexander SR, Brewer ED, Bailey SM, Burns JL. Response to recombinant hepatitis B vaccine (Recombivax HB®) in children with chronic renal failure. [Abstract 14P]. *J Am Soc Nephrol* 1994;5:344.

82. Vazquez G, Mendoza-Guevara L, Alvarez T, et al. Comparison of the response to the recombinant vaccine against hepatitis B virus in dialyzed and nondialyzed children with CRF using different doses and routes of administration. *Adv Perit Dial* 1997;13:291–6.
83. Szmunness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. *N Engl J Med* 1980;303:833–41.
84. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. *N Engl J Med* 1986;315:209–14.
85. Crosnier J, Jungers P, Couroucé A-M, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, haemodialysis patients. *Lancet* 1981;1:797–800.
86. Desmyter J, Colaert J, De Groote G, et al. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff: double-blind placebo-controlled trial. *Lancet* 1983;2:1323–8.
87. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. *Am J Kidney Dis* 1999;33:356–60.
88. Alter MJ, Favero MS, Francis DP. Cost benefit of vaccination for hepatitis B in hemodialysis centers. *J Infect Dis* 1983;148:770–1.
89. CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination—recommendations of the Immunization Practices Advisory Committee (ACIP). *MMWR* 1991;40(No. RR-13):1–25.
90. Rawer P, Willems WR, Breidenbach T, Guttman W, Pabst W, Schütterle G. Seroconversion rate, hepatitis B vaccination, hemodialysis, and zinc supplementation. *Kidney Int* 1987;32(Suppl 22):S149–S152.
91. Mettang T, Weber J, Schenk U, Machleidt C, Kuhlmann U. Intradermal hepatitis B vaccination in nonresponsive hemodialysis patients [Letter]. *Ren Fail* 1993;15:655–6.
92. Rault R, Freed B, Nespors S, Bender F. Efficacy of different hepatitis B vaccination strategies in patients receiving hemodialysis. *ASAIO J* 1995;41:M717–M719.
93. Haubitz M, Ehlerding G, Beigel A, Heuer U, Hemmerling AE, Thoma HA. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. *Clin Nephrol* 1996;45:180–2.
94. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. *Nephrol Dial Transplant* 1997;12:1204–11.
95. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. *JAMA* 1989;261:2362–6.
96. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination [Review]. *Vaccine* 1996;14:1019–27.
97. Mahoney FJ, Stewart K, Hu H, Coleman P, Alter MJ. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. *Arch Intern Med* 1997;157:2601–5.
98. Yuen M-F, Lim W-L, Cheng C-C, Lam S-K, Lai C-L. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. *Hepatology* 1999;29:924–7.
99. Grob PJ, Binswanger U, Zaruba K, et al. Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. *Antiviral Res* 1983;3:43–52.
100. Jilg W, Schmidt M, Weinel B, et al. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. *J Hepatol* 1986;3:190–5.
101. Pasko MT, Bartholomew WR, Beam TR Jr, Amsterdam D, Cunningham EE. Long-term evaluation of the hepatitis B vaccine (Heptavax-B) in hemodialysis patients. *Am J Kidney Dis* 1988;xi:326–31.

102. Fabrizi F, Di Filippo S, Marcelli D, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients: long-term evaluation and cost-effectiveness analysis. *Nephron* 1996;72:536–43.
103. Peces R, de la Torre M, Alcazar R, Urrea JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. *Am J Kidney Dis* 1997;29:239–45.
104. Oliveira PMC, Silva AE, Kemp VL, Juliano Y, Ferraz ML. Comparison of three different schedules of vaccination against hepatitis B in health care workers. *Vaccine* 1995;13:791–4.
105. Yamashiki M, Kosaka Y, Nishimura A. An effective intradermal hepatitis B vaccination. *Vaccine* 1997;15:1618–23.
106. Cardell K, Frydén A, Normann B. Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practice. *Scand J Infect Dis* 1999;31:197–200.
107. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. *JAMA* 1990;264:2231–5.
108. Donahue JG, Muñoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. *N Engl J Med* 1992;327:369–73.
109. Niu MT, Coleman PJ, Alter MJ. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. *Am J Kidney Dis* 1993;22:568–73.
110. Fabrizi F, Martin P, Dixit V, et al. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. *Am J Kidney Dis* 1998;31:647–54.
111. Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland PV. The prevalence of hepatitis C virus antibodies among hemodialysis patients. *Ann Intern Med* 1990;112:958–60.
112. Hardy NM, Sandroni S, Danielson S, Wilson WJ. Antibody to hepatitis C virus increases with time on hemodialysis. *Clin Nephrol* 1992;38:44–8.
113. Jonas MM, Zilleruelo GE, LaRue SI, Abitbol C, Strauss J, Lu Y. Hepatitis C infection in a pediatric dialysis population. *Pediatrics* 1992;89:707–9.
114. Moyer LA, Alter MJ. Hepatitis C virus in the hemodialysis setting: a review with recommendations for control. *Semin Dial* 1994;7:124–7.
115. Selgas R, Martinez-Zapico R, Bajo MA, et al. Prevalence of hepatitis C antibodies (HCV) in a dialysis population at one center. *Perit Dial Int* 1992;12:28–30.
116. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. *MMWR* 1998;47(No. RR-19):1–39.
117. Chan TM, Lok ASF, Cheng IKP, Chan RT. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. *Hepatology* 1993;17:5–8.
118. Sampietro M, Salvadori S, Corbetta N, Badalamenti S, Graziani G, Fiorelli G. Single-tube reverse transcription and heminested polymerase chain reaction of hepatitis C virus RNA to detect viremia in serologically negative hemodialysis patients. *Int J Clin Lab Res* 1995;25:52–4.
119. Stuyver L, Claeys H, Wyseur A, et al. Hepatitis C virus in a hemodialysis unit: molecular evidence for nosocomial transmission. *Kidney Int* 1996;49:889–95.
120. Schröter M, Feucht H-H, Schäfer P, Zöllner B, Laufs R. High percentage of seronegative HCV infections in hemodialysis patients: the need for PCR. *Intervirology* 1997;40:277–8.
121. Le Pogam S, Le Chapois D, Christen R, Dubois F, Barin F, Gaudeau A. Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. *J Clin Micro* 1998;36:3040–3.
122. Alter HJ, Jett BW, Polito AJ, et al. Analysis of the role of hepatitis C virus in transfusion-associated hepatitis. In: Hollinger FB, Lemon SM, Margolis H, eds. *Viral hepatitis and liver disease*. Baltimore, MD: Williams & Williams, 1991:396–402.

123. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. *Semin Liver Dis* 2000;20:17-35.
124. Pol S, Romeo R, Zins B, et al. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. *Kidney Int* 1993;44:1097-100.
125. Gubertini G, Scorza D, Beccari M, et al. Prevalence of hepatitis C virus antibodies in hemodialysis patients in the area of Milan. *Nephron* 1992;61:271-2.
126. Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH, and the Copenhagen Dialysis HCV Study Group. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. *J Infect Dis* 1993;168:1343-8.
127. Sakamoto N, Enomoto N, Marumo F, Sato C. Prevalence of hepatitis C virus infection among long-term hemodialysis patients: detection of hepatitis C virus RNA in plasma. *J Med Virol* 1993;39:11-5.
128. Picciotto A, Varagona G, Gurreri G, et al. Anti-hepatitis C virus antibodies and hepatitis C virus viraemia in haemodialysis patients. *Nephrol Dial Transplant* 1993;8:1115-7.
129. Silini E, Bono F, Cerino A, Piazza V, Solcia E, Mondelli MU. Virological features of hepatitis C virus infection in hemodialysis patients. *J Clin Microbiol* 1993;31:2913-7.
130. Kuhns M, de Medina M, McNamara A, et al. Detection of hepatitis C virus RNA in hemodialysis patients. *J Am Soc Nephrol* 1994;4:1491-7.
131. Oliva JA, Ercilla G, Mallafre JM, Bruguera M, Carrió J, Pereira BJ. Markers of hepatitis C infection among hemodialysis patients with acute and chronic infection: implications for infection control strategies in hemodialysis units. *Int J Artif Organs* 1995;18:73-7.
132. Dussol B, de Lamballerie X, Brunet P, et al. Is hepatitis C virus-RNA detection by nested polymerase chain reaction clinically relevant in hemodialysis patients? *Clin Nephrol* 1996;45:257-60.
133. Pujol FH, Ponce JG, Lema MG, et al. High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. *J Clin Microbiol* 1996;34:1633-6.
134. Caramelo C, Bartolomé J, Albalade M, et al. Undiagnosed hepatitis C virus infection in hemodialysis patients: value of HCV RNA and liver enzyme levels. *Kidney Int* 1996;50:2027-31.
135. Fabrizi F, Lunghi G, Andrulli S, et al. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. *Nephrol Dial Transplant* 1997;12:1394-8.
136. Cristina G, Piazza V, Efficace E, et al. A survey of hepatitis C virus infection in haemodialysis patients over a 7-year follow-up. *Nephrol Dial Transplant* 1997;12:2208-10.
137. Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. *Semin Liver Dis* 1995;15:101-9.
138. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* 1999;341:556-62.
139. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. *Semin Liver Dis* 1995;15:41-63.
140. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *N Engl J Med* 1998;339:1485-92.
141. National Institutes of Health. Chronic hepatitis C: current disease management. Available on the Internet at <<http://www.niddk.nih.gov/health/digest/pubs/chrnhepc/chrnchepc.htm>>. Accessed January 11, 2001.
142. Zacks S, Fried MW. Hepatitis C and renal disease. In: Liang TJ, Hoofnagle JH, eds. *Hepatitis C: biomedical research reports*. San Diego, CA: Academic Press, 2000:329-49.
143. Alter MJ, Margolis HS, Krawczynski K, et al, and the Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team. The natural history of community-acquired hepatitis C in the United States. *N Engl J Med* 1992;327:1899-1905.

144. Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. *N Engl J Med* 1997;336:919–22.
145. CDC. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissue, and semen for evidence of hepatitis B and hepatitis C. *MMWR* 1991;40(No. RR-4):1–17.
146. Kleinman S, Alter HJ, Busch M, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. *Transfusion* 1992;32:805–13.
147. Bouchardeau F, Chauveau P, Le Marrec N, Girault A, Zins B, Couroucé AM. Detection of hepatitis C virus by polymerase chain reaction in haemodialysed patients in relationship to anti-HCV status. *Res Virol* 1993;144:233–42.
148. Seelig R, Renz M, Bottner C, Seelig HP. Hepatitis C virus infections in dialysis units: prevalence of HCV-RNA and antibodies to HCV. *Ann Med* 1994;26:45–52.
149. Al Meshari K, Al Ahdal M, Alfurayh O, Ali A, Devol E, Kessie G. New insights into hepatitis C virus infection of hemodialysis patients: the implications. *Am J Kidney Dis* 1995;25:572–8.
150. Fabrizi F, Lunghi G, Pagliari B, et al. Molecular epidemiology of hepatitis C virus infection in dialysis patients. *Nephron* 1997;77:190–6.
151. Umlauf F, Gruenewald K, Weiss G, et al. Patterns of hepatitis C viremia in patients receiving hemodialysis. *Am J Gastroenterol* 1997;92:73–8.
152. Schneeberger PM, Keur I, van der Vliet W, et al. Hepatitis C virus infections in dialysis centers in the Netherlands: a national survey of serological and molecular methods. *J Clin Microbiol* 1998;36:1711–5.
153. Casanovas Taltavull T, Baliellas C, Sesé E, et al. Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for kidney transplant. *Transplant Proc* 1995;27:2229–30.
154. Dalekos GN, Boumba DS, Katopodis K, et al. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. *Nephrol Dial Transplant* 1998;13:1804–6.
155. Davis GL, Lau JY-N, Urdea MS, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. *Hepatology* 1994;19:1337–41.
156. Roth WK, Lee J-H, Rüster B, Zeuzem S. Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. *J Clin Micro* 1996;34:261–4.
157. Pawlotsky J-M. Measuring hepatitis C viremia in clinical samples: can we trust the assays? [Review] *Hepatology* 1997;26:1–4.
158. Hadler SC, Fields HA. Hepatitis delta virus. In: Belshe RB, ed. *Textbook of Human virology*, 2nd ed. St Louis, MO: Mosby Year Book, 1991:749–65.
159. Lettau LA, Alfred HJ, Glew RH, et al. Nosocomial transmission of delta hepatitis. *Ann Intern Med* 1986;104:631–5.
160. Velandia M, Fridkin SK, Cárdenas V, et al. Transmission of HIV in dialysis centre. *Lancet* 1995;345:1417–22.
161. Sulkowski MS, Thomas DL, Chaisson RC, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. *JAMA* 2000;283:74–80.
162. Keane WF, Shapiro FL, Raji L. Incidence and type of infections occurring in 445 chronic hemodialysis patients. *Trans Am Soc Artif Intern Organs* 1977;xxiii:41–7.
163. Dobkin JF, Miller MH, Steigbigel NH. Septicemia in patients on chronic hemodialysis. *Ann Intern Med* 1978;88:28–33.
164. Kaplowitz LG, Comstock JA, Landwehr DM, Dalton HP, Mayhall CG. A prospective study of infections in hemodialysis patients: patient hygiene and other risk factors for infection. *Infect Control Hosp Epidemiol* 1988;9:534–41.

165. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis: a multicenter prospective survey. *Nephron* 1993;64:95–100.
166. Bloembergen WE, Port FK. Epidemiological perspective on infections in chronic dialysis patients. *Adv Ren Replace Ther* 1995;3:201–7.
167. Bonomo RA, Rice D, Whalen C, Linn D, Eckstein E, Shlaes DM. Risk factors associated with permanent access-site infections in chronic hemodialysis patients. *Infect Control Hosp Epidemiol* 1997;18:757–61.
168. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. *J Am Soc Nephrol* 1998;9:869–76.
169. Tokars JI, Light P, Armistead N, et al. Surveillance for infections in hemodialysis patients: a pilot study [Abstract]. *Infect Control Hosp Epidemiol* 2000;21:101.
170. Stevenson KB, Adcox MJ, Mallea MC, Narasimhan N, Wagnild JP. Standardized surveillance of hemodialysis vascular access infections: 18-month experience at an outpatient, multifacility hemodialysis center. *Infect Control Hosp Epidemiol* 2000;21:200–3.
171. Tokars JI, Alter MJ, Arduino MJ. Nosocomial infections in hemodialysis units: strategies for control. In: Owen WF, Pereira BJG, Sayegh MH, eds. *Dialysis and transplantation: a companion to Brenner and Rector's THE KIDNEY*. Philadelphia, PA: W.B. Saunders Company, 2000, 337–57.
172. Churchill DN, Taylor DW, Cook RJ, et al. Canadian hemodialysis morbidity study. *Am J Kidney Dis* 1992;xix:214–34.
173. Fan P-Y, Schwab SJ. Vascular access: concepts for the 1990s [Review]. *J Am Soc Nephrol* 1992;3:1–11.
174. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *N Engl J Med* 1998;339:584–90.
175. Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicemia in dialysis patients: incidence, risk factors, and prognosis. *Kidney Int* 1999;55:1081–90.
176. CDC. Outbreaks of gram-negative bacterial bloodstream infections traced to probable contamination of hemodialysis machines—Canada, 1995; United States, 1997; and Israel, 1997. *MMWR* 1998;47:55–9.
177. Grohskopf LA, Roth VR, Feiken D, et al. *Serratia liquifaciens* bloodstream infections and pyrogenic reactions associated with extrinsically contaminated erythropoietin [Abstract]. *Infect Control Hosp Epidemiol* 2000;21:136.
178. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. *J Infect Dis* 1995;172:993–1000.
179. Jarvis WR. The epidemiology of colonization. *Infect Control Hosp Epidemiol* 1996;17:47–52.
180. National Kidney Foundation. Dialysis outcomes quality initiative. Clinical practice guidelines. *Am J Kidney Dis* 1997;30(Suppl 3):S137–S240. Available on the Internet at <<http://www.kidney.org>>.
181. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in *Staphylococcus aureus*. Glycopeptide-Intermediate *Staphylococcus aureus* Working Group. *N Engl J Med* 1999;340:493–501.
182. CDC. *Staphylococcus aureus* with reduced susceptibility to vancomycin—Illinois, 1999. *MMWR* 1999;48:1165–7.
183. Raad I, Alrahan A, Rolston K. *Staphylococcus epidermidis*: emerging resistance and need for alternative agents. *Clin Infect Dis* 1998;26:1182–7.
184. Garrett DO, Jochimsen E, Murfitt K, et al. The emergence of decreased susceptibility to vancomycin in *Staphylococcus epidermidis*. *Infect Control Hosp Epidemiol* 1999;20:167–70.
185. Uttley AHC, George RC, Naidoo J, et al. High-level vancomycin-resistant enterococci causing hospital infections. *Epidemiol Infect* 1989;103:173–81.
186. Stroud L, Edwards J, Danzig L, Culver D, Gaynes R. Risk factors for mortality associated with enterococcal blood stream infections. *Infect Control Hosp Epidemiol* 1996;17:576–80.



187. Singer DA, Jochimsen EM, Gielerak P, Jarvis WR. Pseudo-outbreak of *Enterococcus durans* infections and colonization associated with introduction of an automated identification system software update. *J Clin Microbiol* 1996;34:2685–7.
188. Fishbane S, Cunha BA, Mittal SK, Ruggian J, Shea K, Schoch PE. Vancomycin-resistant enterococci in hemodialysis patients is related to intravenous vancomycin use [Letter]. *Infect Control Hosp Epidemiol* 1999;20:461–2.
189. Tokars JI, Gehr T, Parrish J, Qaiyumi S, Light P. Vancomycin-resistant enterococci colonization at selected outpatient hemodialysis centers [Abstract]. *Infect Control Hosp Epidemiol* 2000;21:101.
190. Fogel MA, Nussbaum PB, Feintzeig ID, Hunt WA, Gavin JR, Kim RC. Cefazolin in chronic hemodialysis patients: a safe, effective alternative to vancomycin. *Am J Kidney Dis* 1998;32:401–9.
191. Brady JP, Snyder JW, Hasbargen JA. Vancomycin-resistant enterococcus in end-stage renal disease. *Am J Kidney Dis* 1998;32:415–8.
192. Snyderman DR, Bryan JA, London WT, et al. Transmission of hepatitis B associated with hemodialysis: role of malfunction (blood leaks) in dialysis machines. *J Infect Dis* 1976;134:562–70.
193. Favero MS, Bond WW. Chemical disinfection of medical and surgical materials. In: Block SS, ed. *Disinfection, sterilization, and preservation*, 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 2000: 881–917.
194. Olsen RJ, Lynch P, Coyle MB, Cummings J, Bokete T, Stamm WE. Examination gloves as barriers to hand contamination and clinical practice. *JAMA* 1993;270:350–3.
195. Garner JS and the Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. *Infect Control Hosp Epidemiol* 1996;17:53–80. Available on the Internet at <<http://www.cdc.gov/ncidod/hip>>.
196. American Society of Health-System Pharmacists. *AHFS Drug Information* 1999. Bethesda, MD: American Society of Health-System Pharmacists, 1999:1298–9.
197. US Food and Drug Administration. *Medwatch: the FDA medical products reporting program*. 2000. Available on the Internet at <<http://www.fda.gov/medwatch/safety/2000/safety00.htm#epogen>>.
198. Moyer LA, Alter MJ, Favero MS. Hemodialysis-associated hepatitis B: revised recommendations for serologic screening. *Semin Dial* 1990;3:201–4.
199. CDC. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). *MMWR* 1997;46(No. RR-18):1–42.
200. CDC. Update: recommendations to prevent hepatitis B virus transmission—United States. *MMWR* 1995;44:574–5.
201. CDC. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings. *MMWR* 1993;42(No. RR-2):1–6.
202. CDC. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). *MMWR* 1995;44(No. RR-12):1–13.
203. Title 42: Public health; Chapter IV: Health Care Financing Administration, Department of Health and Human Services; Part 405: Federal health insurance for the aged and disabled; Sections: 405.2136, 405.2140, 405.2150, and 405.2161. 42 CFR 405 (1998).
204. Bolyard EA, Tablan OC, Williams WW, et al, and the Hospital Infection Control Practices Advisory Committee. Guideline for infection control in health care personnel, 1998. *Am J Infect Control* 1998;26:289–354. Available on the Internet at <<http://www.cdc.gov/ncidod/hip>>.
205. Title 29: Labor; Part 1910: Occupational safety and health standards; Section: 1910.1030. 29 CFR 1910.1030 (2000).
206. Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. *Semin Dial* 2000;13:101–7.

## Suggested Readings

- **Cleaning, disinfection, sterilization, and monitoring of hemodialysis fluids and equipment.**

Favero MS, Tokars JI, Arduino MJ, Alter MJ. Nosocomial infections associated with hemodialysis. In: Mayhall CG, ed. Hospital epidemiology and infection control, 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 1999:897–917.

Tokars JI, Alter MJ, Arduino MJ. Nosocomial infections in hemodialysis units: strategies for control. In: Owen WF, Pereira BJJ, Sayegh MH, eds. Dialysis and transplantation: a companion to Brenner and Rector's THE KIDNEY. Philadelphia, PA: W.B. Saunders Company, 2000:337–57.

Association for the Advancement of Medical Instrumentation. AAMI standards and recommended practices, vol. 3: dialysis. Arlington, VA: Association for the Advancement of Medical Instrumentation, 1998.

- **General information on cleaning and disinfection.**

Favero MS, Bond WW. Chemical disinfection of medical and surgical materials. In: Block SS, ed. Disinfection, sterilization, and preservation, 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 2000:881–917.

CDC. Guideline for handwashing and hospital environmental control, 1985. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC. Available on the Internet at <<http://www.cdc.gov/ncidod/hip/Guide/handwash.htm>>.

- **General information on vancomycin-resistant enterococci epidemiology and control in hospitals.**

CDC. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1995;44(No. RR-12):1–13. Available on the Internet at <<http://www.cdc.gov/ncidod/hip>>.

- **Hepatitis C virus infection.**

CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No. RR-19):1–33. Available on the Internet at <<http://www.cdc.gov/hepatitis>>.

- **Preventing infections in patients with central venous hemodialysis catheters.**

National Kidney Foundation. Dialysis outcomes quality initiative. Clinical practice guidelines. Am J Kidney Dis 1997;30(Suppl 3):S137–S240. Available on the Internet at <<http://www.kidney.org>>.

Pearson ML, Hierholzer WJ Jr, Garner JS, et al. Guideline for prevention of intravascular device-related infections: part I. Intravascular device-related infections: an overview. Am J Infect Control 1996;24:262–77. Available on the Internet at <<http://www.cdc.gov/ncidod/hip>>.

- **Standard Precautions and infection control precautions for hospitalized patients.**  
Garner JS and the Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. *Infect Control Hosp Epidemiol* 1996;17:53–80. Available on the Internet at <<http://www.cdc.gov/ncidod/hip>>.
- **Summaries of outbreaks in hemodialysis units and recommendations to prevent similar outbreaks.**  
Favero MS, Tokars JI, Arduino MJ, Alter MJ. Nosocomial infections associated with hemodialysis. In: Mayhall CG, ed. *Hospital epidemiology and infection control*, 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 1999:897–917.  
Tokars JI, Alter MJ, Arduino MJ. Nosocomial infections in hemodialysis units: strategies for control. In: Owen WF, Pereira BJJ, Sayegh MH, eds. *Dialysis and transplantation: a companion to Brenner and Rector's THE KIDNEY*. Philadelphia, PA: W.B. Saunders Company, 2000:337–57.
- **Tuberculosis skin testing and treatment of patients with active disease.**  
CDC. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care facilities, 1994. *MMWR* 1994;43(No. RR-13):1–32. Available on the Internet at <<http://www.cdc.gov/mmwr/preview/mmwrhtml/00035909.htm>>.  
Tokars JI, Miller B. Tuberculin skin testing of ESRD patients [Letter]. *Am J Kidney Dis* 1997;30:456–7.
- **Vaccination and other health-care worker topics.**  
CDC. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). *MMWR* 1997;46(No. RR-18):1–42. Available on the Internet at <<http://www.cdc.gov/ncidod/hip>>.  
Bolyard EA, Tablan OC, Williams WW, et al, and the Hospital Infection Control Practices Advisory Committee. Guideline for infection control in health care personnel, 1998. *Am J Infect Control* 1998;26:289–354. Available on the Internet at <<http://www.cdc.gov/ncidod/hip>>.
- **Vascular access skin site preparation and aseptic technique.**  
National Kidney Foundation. Dialysis outcomes quality initiative. Clinical practice guidelines. *Am J Kidney Dis* 1997;30(Suppl 3):S137–S240. Available on the Internet at <<http://www.kidney.org>>.







---

**Continuing Education Activity  
Sponsored by CDC**

**Recommendations for Preventing Transmission of Infections  
Among Chronic Hemodialysis Patients**

**EXPIRATION — APRIL 27, 2003**

You must complete and return the response form electronically or by mail by **April 27, 2003** to receive continuing education credit. If you answer all of the questions, you will receive an award letter for 2 hours Continuing Medical Education (CME) credit, 0.2 hour Continuing Education Units (CEUs), or 2.2 hours Continuing Nursing Education (CNE) credit. If you return the form electronically, you will receive educational credit immediately. If you mail the form, you will receive educational credit in approximately 30 days. No fees are charged for participating in this continuing education activity.

**INSTRUCTIONS**

**By Internet**

1. Read this *MMWR* (Vol. 50, RR-5), which contains the correct answers to the questions beginning on the next page.
2. Go to the *MMWR* Continuing Education Internet site at <<http://www.cdc.gov/mmwr/cme/conted.html>>.
3. Select which exam you want to take and select whether you want to register for CME, CEU, or CNE credit.
4. Fill out and submit the registration form.
5. Select exam questions. To receive continuing education credit, you must answer all of the questions. Questions with more than one correct answer will instruct you to "Indicate all that apply."
6. Submit your answers no later than **April 27, 2003**.
7. Immediately print your Certificate of Completion for your records.

**By Mail**

1. Read this *MMWR* (Vol. 50, RR-5), which contains the correct answers to the questions beginning on the next page.
2. Complete all registration information on the response form, including your name, mailing address, phone number, and e-mail address, if available.
3. Indicate whether you are registering for CME, CEU, or CNE credit.
4. Select your answers to the questions, and mark the corresponding letters on the response form. To receive continuing education credit, you must answer all of the questions. Questions with more than one correct answer will instruct you to "Indicate all that apply."
5. Sign and date the response form or a photocopy of the form and send no later than **April 27, 2003**, to  
Fax: 404-639-4198                      Mail: MMWR CE Credit  
Office of Scientific and Health Communications  
Epidemiology Program Office, MS C-08  
Centers for Disease Control and Prevention  
1600 Clifton Rd, N.E.  
Atlanta, GA 30333
6. Your Certificate of Completion will be mailed to you within 30 days.

**ACCREDITATION**

**Continuing Medical Education (CME).** CDC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CDC designates this educational activity for a maximum of 2 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**Continuing Education Unit (CEU).** CDC has been approved as an authorized provider of continuing education and training programs by the International Association for Continuing Education and Training and awards 0.2 hour Continuing Education Units (CEUs).

**Continuing Nursing Education (CNE).** This activity for 2.2 contact hours is provided by CDC, which is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation.

**GOAL AND OBJECTIVES**

This *MMWR* provides recommendations regarding the prevention of bloodborne virus and bacterial infections in hemodialysis settings. These recommendations were prepared by CDC staff members after consultation with staff members from other federal agencies and specialists in the field. The goal of this report is to serve as a resource for health-care professionals, public health officials, and organizations involved in the care of patients receiving hemodialysis. Upon completion of this continuing education activity, the reader should be able to describe the recommendations for a) preventing bloodborne virus infections in hemodialysis settings, b) preventing bacterial infections in hemodialysis settings, c) developing and maintaining surveillance systems for infections and other adverse events, and d) developing training and education programs.

**To receive continuing education credit, please answer all of the following questions.**

1. **A comprehensive infection control program in a dialysis setting should include which of the following components? (Indicate all that apply.)**
  - A. Routine serologic testing for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.
  - B. Vaccination of susceptible patients against hepatitis B.
  - C. Surveillance for infections and other adverse events.
  - D. Infection control training and education.
  - E. Isolation of patients who test positive for hepatitis B surface antigen (HBsAg).
  
2. **Which of the following statements regarding hepatitis B vaccination in the dialysis setting are true? (Indicate all that apply.)**
  - A. Hepatitis B vaccine is recommended for all susceptible chronic hemodialysis patients.
  - B. Hepatitis B vaccine is recommended for all susceptible staff members.
  - C. All vaccinees should be tested 1–2 months after completion of the series to determine their response to the vaccine.
  - D. Nonresponders should be given an additional three doses of vaccine and retested.
  
3. **How should chronic dialysis patients who respond to hepatitis B vaccine be followed?**
  - A. No follow-up is necessary.
  - B. Give a booster dose of vaccine annually.
  - C. Test for antibody to HBsAg (anti-HBs) annually and give a booster dose of vaccine if anti-HBs is <10 milli-International Units (mIU)/mL.
  - D. Test for anti-HBs annually, give a booster dose of vaccine if anti-HBs is <10 mIU/ml, and retest for anti-HBs 1–2 months after booster.
  
4. **Which of the following statements regarding the management of HBsAg-positive patients are true? (Indicate all that apply.)**
  - A. HBsAg-positive patients do not have to be isolated from HBV-susceptible patients.
  - B. HBV-immune patients can act as a geographic buffer between HBsAg-positive and HBV-susceptible patients.
  - C. Dedicated equipment should be used for HBsAg-positive patients.
  - D. Staff members who are caring for HBsAg-positive patients can also care for HBV-susceptible patients at the same time.
  - E. Dialyzers should not be reused on HBsAg-positive patients.



5. **Which of the following statements regarding the management of HCV-positive patients are true?**
- A. HCV-positive patients do not have to be isolated from HCV-susceptible patients.
  - B. Staff members who are caring for HCV-positive patients can also care for HCV-negative patients at the same time.
  - C. Dialyzers can be reused on HCV-positive patients.
  - D. All of the above.
  - E. None of the above.
6. **From an infection control standpoint, what is the best way to deliver medications to dialysis patients?**
- A. Deliver medications separately to each patient.
  - B. Use a medication cart to deliver medications to each patient.
  - C. Prepare all medications at each patient's dialysis station and return unused supplies to a common area so they can be used for other patients.
  - D. None of the above.
7. **How should dialysis patients infected or colonized with methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci be treated in the dialysis unit?**
- A. No additional precautions are necessary.
  - B. Contact precautions should always be followed.
  - C. Dedicated equipment should be used.
  - D. If a patient has an infected skin wound with drainage that is not contained by dressings, fecal incontinence, or diarrhea uncontrolled with personal hygiene measures, staff members treating the patient should wear a separate gown and dialyze the patient as far away from other patients as possible.
8. **Which of the following statements are true regarding instruments and supplies that are taken to the patient's dialysis station but not used?**
- A. They can be returned to the clean supply area for use on other patients.
  - B. They must be disposed of or cleaned and disinfected before use on another patient.
  - C. They can be used for another patient if not visibly soiled.
  - D. They can be kept at that dialysis station for use on the next patient.
9. **Which of the following statements are true regarding hand washing?**
- A. Use of a waterless antiseptic hand rub can always be substituted for hand washing.
  - B. Use of a waterless antiseptic hand rub can never be substituted for hand washing.
  - C. Use of a waterless antiseptic hand rub can be substituted for hand washing only if no drug-resistant pathogens are present in the unit.
  - D. Use of a waterless antiseptic hand rub can be substituted for hand washing if hands are not visibly soiled.
10. **Indicate your work setting.**
- A. State/local health department.
  - B. Other public health setting.
  - C. Hospital clinic/private practice.
  - D. Managed care organization.
  - E. Academic institution.
  - F. Other.

- 11. Which best describes your professional activities?**
- A. Hemodialysis patient care/technical support/administration.
  - B. Nephrologist.
  - C. Infection control.
  - D. Laboratory/pharmacy.
  - E. Public health.
  - F. Other.
- 12. I plan to use these recommendations as the basis for . . . (Indicate all that apply.)**
- A. health education materials.
  - B. insurance reimbursement policies.
  - C. local practice guidelines.
  - D. public policy.
  - E. other.
- 13. Each month, approximately how many hemodialysis patients do you or your center treat?**
- A. None.
  - B. 1-5.
  - C. 6-20.
  - D. 21-50.
  - E. 50-100.
  - F. >100.
- 14. How much time did you spend reading this report and completing the exam?**
- A. 1-1.5 hours.
  - B. More than 1.5 hours but fewer than 2 hours.
  - C. 2-2.5 hours.
  - D. More than 2.5 hours.
- 15. After reading this report, I am confident I can describe the recommendations for preventing bloodborne virus infections in hemodialysis settings.**
- A. Strongly agree.
  - B. Agree.
  - C. Neither agree nor disagree.
  - D. Disagree.
  - E. Strongly disagree.
- 16. After reading this report, I am confident I can describe the recommendations for preventing bacterial infections in hemodialysis settings.**
- A. Strongly agree.
  - B. Agree.
  - C. Neither agree nor disagree.
  - D. Disagree.
  - E. Strongly disagree.

17. **After reading this report, I am confident I can describe the recommendations for developing and maintaining surveillance systems for infections and other adverse events.**
- A. Strongly agree.
  - B. Agree.
  - C. Neither agree nor disagree.
  - D. Disagree.
  - E. Strongly disagree.
18. **After reading this report, I am confident I can describe the recommendations for developing training and education programs.**
- A. Strongly agree.
  - B. Agree.
  - C. Neither agree nor disagree.
  - D. Disagree.
  - E. Strongly disagree.
19. **The objectives are relevant to the goals of this report.**
- A. Strongly agree.
  - B. Agree.
  - C. Neither agree nor disagree.
  - D. Disagree.
  - E. Strongly disagree.
20. **The tables and figure are useful.**
- A. Strongly agree.
  - B. Agree.
  - C. Neither agree nor disagree.
  - D. Disagree.
  - E. Strongly disagree.
21. **Overall, the presentation of the report enhanced my ability to understand the material.**
- A. Strongly agree.
  - B. Agree.
  - C. Neither agree nor disagree.
  - D. Disagree.
  - E. Strongly disagree.
22. **These recommendations will affect my practice.**
- A. Strongly agree.
  - B. Agree.
  - C. Neither agree nor disagree.
  - D. Disagree.
  - E. Strongly disagree.

**23. How did you learn about this continuing education activity?**

- A. Internet.
- B. Advertisement (e.g., fact sheet, *MMWR* cover, newsletter, or journal).
- C. Coworker/supervisor.
- D. Conference presentation.
- E. *MMWR* subscription.
- F. Other.

**Correct answers for questions 1-9.**  
1. A, B, C, D, E; 2. A, B, C, D; 3. C; 4. B, C, E; 5. D; 6. A; 7. D; 8. B; 9. D.

**MMWR Response Form for Continuing Education Credit  
April 27, 2001/Vol. 50/No. RR-5**

**Recommendations for Preventing Transmission of Infections  
Among Chronic Hemodialysis Patients**

*To receive continuing education credit, you must*

- 1. provide your contact information;*
- 2. indicate your choice of CME, CEU, or CNE credit;*
- 3. answer all of the test questions;*
- 4. sign and date this form or a photocopy;*
- 5. submit your answer form by April 27, 2003.*

*Failure to complete these items can result in a delay or rejection of your application for continuing education credit.*

Detach or Photocopy

\_\_\_\_\_  
Last Name First Name

\_\_\_\_\_  
Street/Address or P.O. Box

\_\_\_\_\_  
Apartment or Suite

\_\_\_\_\_  
City State Zip Code

Check One

- CME Credit
- CEU Credit
- CNE Credit

Fill in the appropriate blocks to indicate your answers. Remember, you must answer all of the questions to receive continuing education credit!

- |   |   |
|---|---|
| 1. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                             | 13. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E <input type="checkbox"/> F |
| 2. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D  | 14. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D   |
| 3. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D  | 15. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                            |
| 4. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                             | 16. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                            |
| 5. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                             | 17. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                            |
| 6. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D  | 18. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                            |
| 7. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D  | 19. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                            |
| 8. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D  | 20. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                            |
| 9. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D  | 21. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                            |
| 10. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E <input type="checkbox"/> F | 22. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                            |
| 11. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E <input type="checkbox"/> F | 23. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E <input type="checkbox"/> F |
| 12. <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> C <input type="checkbox"/> D <input type="checkbox"/> E                            |   |

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date I Completed Exam

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

## MMWR

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to [listserv@listserv.cdc.gov](mailto:listserv@listserv.cdc.gov). The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at <http://www.cdc.gov/mmwr/> or from CDC's file transfer protocol server at <ftp://ftp.cdc.gov/pub/Publications/mmwr/>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.